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Abstract
Alzheimer’s  disease (AD) is  the most  common neurodegenerative disorder and the 
main cause of dementia. Diagnostic hallmarks of AD are neuritic plaques and neurofib-
rillary tangles in various regions of the brain. About 5% of the patients show mutations 
in genes involved in the pathogenesis of AD. These mutated genes were used to gen-
erate animal models for studying unclear mechanisms of the pathogenesis and to de-
velop new treatment  strategies  for  AD.  In  one  of  these  models,  the  mouse  model 
Tg2576, overexpression of human amyloid precursor protein (APP) carrying two point 
mutations leads to the development of amyloid plaques, the major hallmark of AD. One 
strategy to clear these plaques is active immunization. The vaccination of APP trans-
genic mice results in development of antibody titres highly specific against amyloid beta 
(Aβ), the main component of the amyloid plaques in the brain. This vaccination leads to 
lowering of AD pathology in mice. 
AFFiRiS develops such vaccines based on the AFFITOPE technology which uses short 
peptides mimicking parts of the amyloid beta peptide that is produced naturally in the 
body. The induced antibodies bind with high affinity to Aβ and thereby clear the charac-
teristic deposits. In addition the cognitive function of vaccinated animals is ameliorated 
compared to the transgenic untreated mice, which has been shown in behavioural test. 
In this diploma thesis the impact of active AFFITOPE vaccination on different aspects 
of neuropathologic alterations in transgenic animals will be investigated. Among the ex-
amined parameters are different neurotransmitters, the structure and integrity of neur-
ons, pre- and postsynaptic markers and the levels of neuroprotective factors. Changes 
concerning the structure and functionality of neurons could be determined by using the 
dendritic marker MAP2 in the immunofluorescence approach. Moreover, immunofluor-
escent staining of α-synuclein, a presynaptic protein, revealed alterations in its localisa-
tion and its grade of accumulation. Other postsynaptic factors, like PSD95, Drebrin and 
ARC/Arg3.1 were compared by Western Blotting showing no differences between wild-
type and transgenic animals. Finally, neither in neurotransmitter nor in concentrations 
of the neuroprotective factor secreted APPα significant changes could be determined. 
In some synaptic markers pathologic alterations could be detected. The MAP2 density 
is lowered in transgenic animals compared to wildtype mice. In comparison with vaccin-
ated animals trends towards the wildtype phenotype could be constituted. However, no 
significant differences were reached. The same is true for α-synuclein as a marker for 
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presynaptic  alterations.  Vaccinated  transgenic  animals  show  a  decrease  of  these 
pathologic hallmarks. Concluding one can say that ameliorations of neuropathologic al-
terations could be detected in vaccinated animals. 
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Zusammenfassung
Die Alzheimer Krankheit (AD, engl.  Alzheimer's Disease) ist die häufigste neurodege-
nerative Erkrankung und Verursacher von Demenz. Diagnostische Kennzeichen von 
AD sind neuritische Plaques und neurofibrilläre “tangles” in verschiedenen Hirnregio-
nen. Circa 5% der AD-Patienten tragen Mutationen in Genen, die an der Pathogenese 
von AD beteiligt sind. Diese Mutationen werden genutzt um Tiermodelle zu generieren 
um unbekannte Mechanismen der Pathogenese zu studieren und um neue Behand-
lungsstrategien  für  AD  zu  entwickeln.  In  einem  dieser  Modelle,  dem  Mausmodell 
Tg2576,  führt  die  Überexpression von humanem amyloiden Vorläuferprotein (APP), 
das  zwei  Punktmutationen  trägt,  zu  der  Entstehung  von  amyloiden  Plaques,  dem 
Hauptmerkmal von AD. Eine Möglichkeit die Plaques zu entfernen stellt die aktive Im-
muntherapie dar. Die Impfung APP transgener Mäuse führt zur Induktion von Antikör-
pertitern spezifisch gegen amyloid beta (Aβ), dem Hauptbestandteil der Plaques. Diese 
Impfung führt zu einer Reduktion der AD Pathologie. 
AFFiRiS entwickelt solche Impfstoffe basierend auf der AFFITOPE Technologie, in der 
kurze Peptide benutzt werden, welche körpereigenes Aβ nachahmen. Die induzierten 
Antikörper binden mit hoher Affinität an Aβ und tragen dadurch zur Beseitigung der Ab-
lagerungen bei. Zusätzlich konnte in Verhaltenstests eine Verbesserung der kognitiven 
Fähigkeiten der geimpften im Vergleich zu unbehandelten transgenen Mäusen gezeigt 
werden. 
In dieser Diplomarbeit wurde der Einfluss der aktiven AFFITOPE Impfung auf verschie-
dene Aspekte neuropathologischer Veränderungen untersucht. Unter den betrachteten 
Faktoren befinden sich verschiedene Neurotransmitter, neuronale Struktur- und Integri-
tätsindikatoren, prä- und postsynaptische Marker als auch neuroprotektive Faktoren. 
Bezüglich der Strukturen und Funktionalität von Neuronen konnten mit Hilfe des Den-
dritenmarkers MAP2 mit Hilfe von Immunfluoreszenzfärbungen Veränderungen nach-
gewiesen werden. Zudem konnten Veränderungen in der Lokalisation und der Anhäu-
fung von α-synuclein, einem präsynaptischen Protein, mittels Immunfluoreszenz darge-
stellt werden. Andere postsynaptische Faktoren wie PSD95, Drebrin und ARC/Arg3.1 
wurden mittels Western Blot in transgenen versus wildtyp Tieren verglichen. Letztend-
lich wurden weder in Neurotransmitterkonzentrationen noch in Levels des neuroprotek-
tiven Faktors sAPPα signifikante Unterschiede in den verschieden behandelten Tieren 
gemessen.  In  einigen Synapsenmarkern konnten pathologische Veränderungen ge-
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zeigt werden. Die MAP2 Dichte ist in transgenen Tieren im Vergleich zu Wildtype ver-
ringert. In geimpften transgenen Tieren konnte ein Trend Richtung Phänotyps des Wild-
typs festgestellt werden, jedoch mit nicht-signifikanten Unterschieden. Dasselbe gilt für 
den Präsynapsenmarker α-synuclein. Geimpfte Tiere zeigen eine Verringerung der pa-
thologischen Kennzeichen. Allgemein betrachtet konnten Verbesserungen der neuro-
pathologischen Veränderungen in geimpften versus nicht geimpften transgenen Mäu-
sen gezeigt werden. 
iv
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 1 Introduction
 1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of dementia. It is an incurable 
neurodegenerative  disease  affecting  the  elderly.  The  characteristic  symptomatic 
hallmarks of AD are cognitive, behavioural and functional decline. The neuropatho-
logy is marked by formation of neuritic plaques composed of aggregated β-amyloid 
peptide, neurofibrillary tangles made up of hyperphosphorylated Tau protein and 
the early loss of neocortical synapses [1]. It is a progressive and terminal illness, 
but death of patients is caused by external factors due to continuous worsening of 
the physical and psychical state [2].
 1.1.1 History of AD
AD was first described by Alois Alzheimer in his talk at the meeting of psychiatrists 
in 1906 [1]. He depicted the behavioural symptoms of his patient Auguste Deter. In 
the early stages of the disease, she lost her short-term memory and also her mood 
was changing fast from one extreme to the contrary. Later, also her long-term po-
tentiation (LTP) was affected and Deter was not longer capable to manage daily 
life. After her death, Alzheimer examined Auguste Deter’s brain by microscopy and 
different staining methods. He found a highly diminished brain mass, enlarged vent-
ricles and protein deposits in the cortex. The congophilic deposits he named “amyl-
oid plaques” and the fibrillar structures he entitled as “neurofibrillary tangles” [3]. All 
these behavioural and pathologic characteristics are still the standard of diagnosis 
of AD. 
 1.1.2 Incidence and diagnosis
Nowadays, the number of patients continuously rises, particularly in the industrial 
world where society is ageing. Worldwide more than 20 million people are affected 
by AD [4]. AD belongs to the most costly diseases in these parts of the world as in 
general long-term care is needed. In humans the pathology arises beyond the age 
of 70  [5],  [6], except the early-onset hereditary form of the disease which even 
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starts around the age of 45-60 years  [7]. The symptoms are characterized as in 
other dementias by the loss of memory and lowering of cognitive capabilities. Pa-
tients are strongly affected in their daily life. Especially in the advanced stage of the 
disease they are completely dependent on caregivers. The life expectancy in AD is 
decreased; however it is not possible to give each individual a general prediction at 
the time point of diagnosis as there are persons living decades with AD and others 
only a few years. On average death occurs 9 years after diagnosis [8]. The causes 
of death are external factors like downfalls, bedsores and pneumonia [2]. 
Until now, in the preclinical stage of AD there are no reliable symptoms established 
to  make a  confident  diagnosis  possible  before  the  manifestation  of  irreversible 
damage of the brain. Cognitive tests can be carried out which give a certain prob-
ability of the existence of AD. However, this technique as well, is the more secure 
the further the disease is already progressed. Also the similarity to other forms of 
dementia makes it hard to diagnose AD. Often the disease is already advanced at 
the time point of a definitive diagnosis. This makes later treatment more difficult. 
 1.1.3 Genetic causes of AD
The pathogenesis of AD is not completely understood. It is predicted to be a inter-
play  between  different  factors.  Genetic  aspects,  life  style,  training  of  the  brain 
memory function and ageing are important aspects in developing the disease. Es-
timations on the impact of familial AD defined through mutations in relevant genes, 
are diverging from about 0.1% of all AD patients [9] to 5-10% [10]. 
There are numerous point mutation sites known in the amyloid precursor protein 
(APP). Each substitution of an amino acid leads to an aberrant way of processing 
and deposition of the APP (see chapter 1.2). Protein aggregation and deposition of 
amyloid β (Aβ), a cleavage product of APP, result in so called senile plaques, which 
are predicted to be highly neurotoxic. In this context the elevated risk of developing 
AD in patients with chromosomal aberration should be mentioned. In the case of tri-
somy 21, the chromosome 21, on which the APP gene is located, is present in trip-
licate. This occurs by a non-disjunction event during meiosis. Hence, Aβ might be 
expressed at higher levels (the so called gene dosage effect) which can be the trig-
ger for increased AD-like pathology development [4], [11], [12]. 
Presenilins are a family of transmembrane proteins and also seem to be involved in 
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AD pathogenesis. Presenilin 1 (PS1; also PSEN1) and PS2 function as subunits in 
the  γ−secretase which is involved in processing events of the amyloid precursor 
protein. In some forms of the early-onset familial AD PS1/2 genes are mutated [5], 
[13].
Another genetic prevalence being discussed is one specific allele of the Apolipopro-
tein E (ApoE). The ApoE4 allele seems to be related with the late-onset and the 
sporadic form of AD [14]. Homozygotes for the ApoE4 allele show a higher preval-
ence for AD development than heterozygote ApoE4 carriers. Recent data imply that 
the probability to come down with AD is enhanced up to 90% in ApoE4 carriers 
compared to 20% in non ApoE4 carriers  [15]. The mechanism how ApoE4 inter-
feres with the progression of AD is not well understood. It can be assumed that 
ApoE4 plays a role in the formation of amyloidogenic plaques [13] and its clearance 
[16]. Proteolytically cleaved ApoE4 also seems to influence the phosphorylation of 
Tau protein [17]. 
Another protein involved in the pathology of AD is the highly soluble microtubuli as-
sociated protein Tau. It stabilizes microtubuli of neurons in the central nervous sys-
tem, but it is rare in the rest of the body. Its hyperphosphorylation through different 
tyrosine or serine kinases leads to destabilization of microtubules and to aggrega-
tion of Tau. The so formed aggregates in neurons are called neurofibrillary tangles 
(NFTs)  [4]. They are highly neurotoxic and responsible for synapse degeneration 
and neuron loss [18]. This is explained by the detachment of hyperphosphorylated 
and aggregated Tau from the microtubuli. This is followed by their breakdown, con-
sequent failure in intracellular transport and neuron degeneration. The mutated hu-
man PS1 gene has been shown to be involved in Tau hyperphosphorylation  [11]. 
Moreover, the presynaptic protein α-synuclein is believed to interact with Tau and 
thereby promotes its phosphorylation at specific amino acid residues [13], [19]. The 
complete role of the Tau protein in the pathogenesis of AD is not well understood, 
but there are several other neurodegenerative diseases, in which Tau is involved as 
well, e.g. FTDP-17, pick's disease, PSP [20]. 
 1.2 The Amyloid Precursor Protein 
The amyloid precursor protein (APP) is a conserved type I membrane protein. The 
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human APP gene is located on the long arm of chromosome 21. It is about 240kb 
long and made up of at least 18 exons [21]. The full length APP is 770 amino acids 
long and the polypeptides migrate between 110-140kD in gel electrophoresis [10]. 
There are three different major isoforms of the protein, APP695, APP751 and AP-
P770 caused by alternative splicing. The longer variants contain a Kunitz-type ser-
ine protease inhibitor domain, which is lacking in the shorter isoform. APP695 is 
predominantly expressed in neurons, whereas the other isoforms are ubiquitously 
expressed  [22]. The whole protein consists of a small intracellular C-terminal do-
main, a transmembrane region and a larger extracellular N-terminal domain. The 
protein is posttranslationally modified through glycosylation, phosphorylation and 
tyrosine sulphation. Its physiological function was unknown for a long time, but re-
cently there is evidence for its involvement in synaptogenesis. APP is anterogradely 
transported targeting synapses the place in cells where it is active [12]. Its expres-
sion is elevated during brain injuries and APP plays an essential role in neuronal 
migration as well as neuron plasticity. This could be shown among others by gener-
ating an APP loss of function mutation in mice [21].
 1.2.1 APP Processing 
Figure 1: Schematic depiction of APP processing. EC: extracellular, TM: transmembrane, IC: 
intracellular, Aβ peptide is depicted in red (taken from Zheng and Koo, 2006)
Proteases of the secretase family are responsible for the different final products of 
APP.  α-  and  β-secretases  proteolytically  cleave  APP  in  the  extracellular  part 
(between aa 687 and 688 or 671 and 672, respectively); the γ−secretase, which is a 
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multiprotein complex including presenilins often being mutated in AD (see chapter 
1.1.3), cleaves in the membrane-spanning domain (3 cleavage sites between aa 
711 and 721) (Fig.1). Always two consecutive processing steps take place. The 
non-amyloidogenic  pathway consists  of  a  first  cut  by the  α-secretase releasing 
sAPPα at the N-Terminus and APP-C-TerminalFragment(CTF)α. After this cleavage 
step the amyloidogenic processing is no longer permitted. The APP-CTFα is further 
processed by the γ−secretase resulting in the APP intracellular domain (AICD) and 
a 3kD small product, called p3. The pathological way of processing starts with a cut 
by the β-secretase (also known as BACE1 – β-site APP cleavage enzyme) resulting 
in the soluble APPβ and the APP-CTFβ. The latter cleavage product is further pro-
cessed by the γ secretase releasing amyloid  β and AICD  [10]. In healthy people 
both ways of processing exist likewise [10]. 
Figure 2: Part of the APP amino-acid sequence; mutations are highlighted; 
mutations are named after the nationality or location of the first family in which 
that specific mutation was demonstrated. Red: amyloid beta sequence. A, alan-
ine; D, aspartic acid; E, glutamic acid; F,phenylalanine; G, glycine; H, histidine; 
I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, 
glutamine; R, arginine;  S, serine; T,  threonine; V, valine; Y,  tyrosine. (taken 
from van Dam and De Deyn, 2006)
There are degradation (e.g.  ubiquitination followed by proteasomal  degradation) 
and clearing mechanisms of the amyloidogenic APP cleavage products, which do 
not work properly any longer in AD patients [16]. Hence, accumulation of abnormal 
processed fragments and their latter aggregation occurs. The conformation of Aβ 
from the soluble form into aggregates is a critical and not well understood mechan-
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ism in AD [13]. However, it is known, that plaque formation also take place in brains 
of older intellectually normal persons not showing any dementia like symptoms [23]. 
Thus, the defect in processing is linked to ageing. Other linked aspects are muta-
tions in the gene (Fig.2).  Mostly,  mutated sites  are  near  the cleavage sites for 
secretases. Thus, altered processing followed by changes in the balance of the res-
ulting products proceed [24].
 1.2.2 Aβ
Aβ is a secreted, approximately 4kD small polypeptide derived from APP constitut-
ing the principle protein of senile plaques in AD [25]. Two kinds of soluble Aβ pep-
tide  are  generated  during  APP processing:  Aβ1-40  and  Aβ1-42,  depending  on 
which cleavage site is used by the γ−secretase complex. The latter is less frequent 
(5-15% of total Aβ) [12], but shows more tendency to aggregate [10]. Therefore it is 
believed to act as a seed for the later neuritic plaque formation. This assumption 
can be explained as the two additional amino acid residues (namely isoleucine and 
alanine) of one Aβ42 peptide strongly bind to the amino acids 34 (leucine) and 35 
(methionine) of another monomer. This leads to the characteristic β-sheet formation 
[26], [27]. 
 1.2.3 sAPPα
It has been observed that APP expression is elevated during neuronal maturation 
and differentiation as well as in brain injury  [21]. In these processes more of the 
secreted sAPPα (sAPPα) fragment is released which is believed to play an import-
ant role in the healing and regenerative process as a neuroprotective factor. It has 
been described that sAPPα mainly supports full-length APP in its function of neurite 
outgrowth [28], [29]. In addition there is evidence that sAPPα is involved in regulat-
ing stem cells. It stimulates the proliferation of EGF (epidermal growth factor) -re-
sponsive  stem cells  in  the  subventricular  zone (acting  as  a  cofactor  for  EGF). 
Moreover, sAPPα induces the differentiation of neuronal stem cells into the astro-
cytic cell lineage [12]. For all these events, sAPPα is necessary but not sufficient. 
Another known function of sAPPα is normalizing the calcium homeostasis in neur-
ons which is protective against excitotoxycity [6]. 
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 1.2.4 The amyloid cascade hypothesis
The hypothesis was established to clarify the link between the abnormal accumula-
tion of Aβ peptide and neurodegeneration in AD. 
Figure 3: Scheme of a hypothetical progression of pathogenetic steps in familial 
forms of AD. For detailed description of the cascade see text. (taken from Selkoe, 2001)
The previously described soluble Aβ fragments are naturally produced. The hypo-
thesis indicates that the abnormally increased concentrations of fibrilar Aβ42 com-
pared to the soluble Aβ40 in AD favours the development of typical plaques. Mono-
meric Aβ42 form β-sheet structures, followed by protofibril- and fibrilformation [30]. 
Finally, they undergo dense aggregation and build up mature amyloid plaques [31]. 
Aβ40 is assumed to only co-deposit in the mature neuropathologic plaques  [10]. 
The Aβ hypothesis states that the following neuropathologic damage that occur in 
7
AD are all triggered by Aβ deposition. These include inflammatory responses, neur-
onal loss, hyperphosphorylation of Tau and many more (Fig.3). 
Initially,  the  correlation  between  fibrilar  Aβ and  neurotoxicity  has  been  demon-
strated by application of synthetic Aβ monomers on neuronal cell cultures. The re-
searchers found out, that only “matured” Aβ solution (allowed to aggregate during 3 
day incubation) shows toxic properties, but not freshly applied Aβ monomers [32]. 
However, the hypothesis is disputed among scientists. Critical points are the partial 
correlation between the amount of neuritic plaques and the degree of dementia. 
Furthermore, as mentioned before (see chapter 1.2.1) also non-demented aged in-
dividuals show plaques. Besides high neuron loss could be shown in areas of the 
brain with no plaque load [32]. 
Another upcoming idea is the oligomer hypothesis which claims soluble Aβ42 oli-
gomers to be the main cause of toxicity. This prediction was made in connection 
with an experiment in which Aβ fibril formation was inhibited resulting in increased 
cell toxicity. This phenomenon was explained by the shifted balance in favour of oli-
gomeric Aβ [33]. 
 1.3 Alterations in the neuronal network and AD associated 
pathologic alterations
In brains of AD patients neuropathologic alterations have been observed. All these 
findings are more or less associated with the presence of Aβ deposits or NFTs. 
Mostly,  it  is  still  under  investigation  which  event  or  pathologic  alteration  in  the 
pathogenesis of AD is the cause of or leads to other AD related phenomenons. 
The first change in AD brains to be mentioned is the loss of neurons and synapses. 
Synapses are the place in the brain were transmission, processing and storage of 
information take place. Synapses exist between two neurons, thus building a huge 
interconnecting network. As the main cause of synaptic loss, death of neurons is 
mentioned [34]. Moreover, synapses of living neurons degrade in case that the con-
nected synapses decease in consequence of dying neurons. It has been shown 
that synapses of living neurons containing NFTs are more susceptible to degenera-
tion than those of non-NFT containing neurons [35]. The analysis of synaptic altera-
tions is done by using common pre- and postsynaptic markers like α-synuclein and 
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PSD95. The breakdown of synapses leads to altered accumulation of these pre- 
and postsynaptic factors. 
Equally,  neurotransmitter levels can be analysed. Death of certain neurons, e.g. 
cholinergic neurons cause impairment in the concentrations and effectiveness of 
the transmitter acetylcholine. 
Furthermore, dendritic markers can be used to highlight alterations in the structure 
of  neurons  and  their  branches in  AD affected  brains.  One of  these  markers  is 
MAP2, which is a microtubuli associated protein only present in dendrites but not in 
axons (Tau is  the equivalent  protein  in  axons).  Other  markers  are  Drebrin  and 
ARC/Arg3.1. Both are expressed in dendritic spines. Spine plasticity is involved in 
motivation, learning and memory. Dendritic spines are highly flexible, although after 
LTP they can get very stable. 
Cerebral amyloid angiopathy is a side effect of Aβ accumulation. Amyloid β depos-
ition also takes place in blood vessels causing their weakening and occlusion. This, 
in further consequence, leads to cerebral microhemorrhages  [36] and thus might 
cause stroke. CAA incidence varies with the APP mutation [16]. 
Figure 4: Summery of the impairments caused by pathogenic amyloid β assemblies. For 
details see text. (taken from Roberson and Mucke, 2006)
Another early pathological manifestation in AD is astrogliosis. It describes the in-
creased accumulation of astrocytes. Astrocytes are responsible for supporting, pro-
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tecting and nourishing neurons [4]. They are socialised within the plaques as they 
also fulfil their clearing function as immune cells of the central nervous system [4]. 
Microglia are also part of the immune system and responsible for inflammation at 
site with abnormal accumulation of proteins such as Aβ or Tau. What is meant to 
clear harmful agents can also cause damage to neuronal cells (for summary see 
Fig.4). 
 1.4 Therapeutic strategies against AD
Up to  now there is  no cure  available  for  AD.  There are  medications  like  acet-
ylcholine (ACh) esterase inhibitors and N-methyl  D-aspartate receptor (NMDAR) 
agonists.  The  former  is  applied  to  counteract  the  loss  of  active  acetylcholine 
caused by death of cholinergic neurons. This is mediated by inhibiting the enzyme 
ACh esterase which triggers the conversion of acetylcholine into the inactive meta-
bolites acetate and choline [37], [38]. The second pharmaceutical blocks NMDA re-
ceptors.  This  prevents  overstimulation  through  the  excitatory  neurotransmitter 
glutamate binding normally to the receptor. This would provoke excitotoxicity, which 
implies the damage of nerve cells by an increased influx of calcium ions [39]. These 
medications are used as symptomatic treatment. They are unable to halt or only to 
slow down the progress of AD. For long term treatment, a remaining promising and 
in the end very effective approach to fight this widespread disease, could be im-
munotherapy. 
 1.4.1 Active immunization against Aβ
The medical term “immunotherapy” can be defined as “treatment of a disease with 
therapeutic agents that promote or inhibit immune responses” [40]. 
Vaccination is one kind of immunotherapy. It can be distinguished between passive 
and active immunization as well as vaccination as prophylactic or therapeutic ap-
proach. Passive immunization in general implicates the direct injection of specific 
monoclonal antibodies into the person (or animal) to prevent or combat already ex-
isting diseases. This vaccination has to be repeated when the antibody titer in the 
blood stream decreases. 
Active immunization consists of the appliance of an antigen, the vaccine, to evoke 
an immune response. For example, in the case of many viral infections attenuated 
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or killed virus particles were injected to provoke an immune response against the 
specific virus. In the case of a later infection with the virus, memory B-cells are able 
to produce high amount of the specific antibody and the infection can be cleared 
easily and rapidly by the adaptive immune system. The antigen is mostly coupled to 
an adjuvant to boost the immune response. Active immunization against Aβ has 
been shown to be quite complicated since the blood brain barrier has to be crossed 
by the induced antibodies. In a vaccination approach using the original full-length 
Aβ sequence, patients came down with meningoencephalitis in the clinical trial [4], 
[41]. It is now believed that this effect was due to a T-cell response since all af-
fected patients showed CD4+ and CD8+ T-cell infiltrates in the brain [4]. 
Figure  5:  Schematic  drawing of  different  vaccination  approaches 
against Aβ. a)&b) active immunizations leading to Aβ-specific antibody 
production, a) full length Aβ42 peptide is used for immunization, b) an Aβ 
fragment is coupled to a carrier protein to stimulate required T-cell  re-
sponse, c) passive immunization by injecting anti-Aβ antibodies. (taken 
from Schenk, 2002)
Therefore AFFiRiS AG is developing a safer form of Aβ vaccine [42], [43]. AFFiRiS 
AG is aiming to develop secure active vaccines against different widespread dis-
eases  as  atheriosclerosis,  high  blood  pressure,  Parkinson's  disease  (PD)  and 
Alzheimer's Disease. The fundamental technology consists of short peptides called 
AFFITOPEs, which mimic parts of the amino acid sequence of the target molecule. 
This induces antibody production against the target protein by B-cell stimulation. In-
flammation caused by (cytotoxic) T-cells is not provoked since the peptides are too 
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short to be recognized by them. T-helper cells releasing cytokines needed for B-cell 
maturation and generation of antibodies are stimulated by coupling the peptide for 
vaccination to a carrier protein and an adjuvant (Fig.5) [44], [40]. In the case of AD 
the peptide is mimicking the N-terminal region of the Aβ peptide. 
In different preclinical studies it could be shown that in vaccinated Tg2576 mice the 
amount  of  both  soluble  and aggregational  amyloidogenic  Aβ is  significantly  de-
creased compared to non-vaccinated transgenic mice. In immunohistochemical in-
vestigations it has been shown, that the area of plaques and the overall plaque load 
in the vaccinated animals were lowered (Mandler et al., manuscript in preparation). 
In accordance to this, amelioration of the cognitive function could be determined in 
behavioural tests like the morris water maze. Since these results of the preclinical 
experiments in the animal model are quite promising, AFFiRiS AG already started 
the clinical trials. 
 1.5 The mouse model
The different occurring mutations in the APP as well as in PS1 and PS2 have been 
used to generate mouse models for AD. In this study the Tg2576 animal model has 
been examined. The mutant human amyloid precursor protein (APP) containing the 
double  Swedish  mutation  (K670N,  M671L)  is  brought  into  a  129S2  laboratory 
mouse strain. The transgene is under the control of the hamster prion promoter. 
This  promoter  allows preferential  expression in  the central  nervous system  [11] 
leading to highest accumulation of the transgene in the brain [31]. However, human 
APP expression is not confined to the brain, but can also be detected in other tis-
sues like heart, skin,  muscle and many more  [31], [45].  The transgenic animals 
show 5 to 6 fold overexpression of APP compared to a wildtype non-transgenic an-
imal [46]. The onset of formation of senile plaques with Congo Red-positive cores is 
about 7-8 months of age [31]. The most predominant form of Aβ present in Tg2576 
is  Aβ1-40  [31],  [47], whereas this  is  only the case in  33% of  AD patients  [48]. 
Moreover,  in  Tg2576  only  5% of  the  Aβ is  N-terminally  truncated  or  modified, 
whereas in human AD brains this is the case in 69 -85% of insoluble Aβ [31]. In the 
water maze strong behavioural deficits of the animals could be observed [47], [49]. 
Compared to other models, these mice do not show a severe phenotype, but in 
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general, one can say that this animal model provides all the features for investiga-
tion of Aβ plaque formation. Tg2576 mice do not reflect all aspects of AD like for ex-
ample hyperphosphorylated Tau protein that  gives rise to neurofibrillary tangles. 
Thus, for research on Tau protein and its influence on AD, another mouse model 
has to be used.
 1.6 Aim of the thesis
In addition to the reduction of plaque load and plaque area in the affected brain re-
gions, active vaccination against Aβ should lead to an improvement of the neuronal 
functionality and integrity as well as an increase in the synaptic density. In this work 
some characteristic markers for  these features were investigated in the Tg2576 
mouse model. First, general comparisons of wildtype and transgenic animals were 
carried out by biochemical and immunohistochemical analysis. In the case of de-
tectable pathologic alterations concerning protein concentrations or localisation in 
transgenic animals, vaccinated transgenic animal were analysed focusing on these 
AD associated pathologic hallmarks and their possible amelioration after active im-
munotherapy. Neurotransmitter levels as well as neuroprotective factor concentra-
tions were measured by enzyme linked immunosorbent assay kits provided by dif-
ferent companies. Amounts of pre- and postsynaptic proteins in differently treated 
animals were compared using western blotting. Thus, homogenates of complete 
brain hemispheres were analysed. Immunohistochemistry was used to determine 
light alterations of certain markers in distinct brain regions. With this method also 
the pathological phenotype of neurons neighbouring the neurotoxic Aβ aggregates 
could be visualised.
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 2 Methods and Material
 2.1 Genotyping PCR
Genomic DNA from mouse tail  tips was used for genotyping PCR to detect the 
presence of the transgene. As internal control, primers for a housekeeping gene 
were used.
 2.1.1 Digestion of mouse tail tips and Extraction of DNA
For genotyping mouse tail tips were used for genomic DNA purification (genomic 
DNA purification system; Promega). Mouse tail tips (2-3mm) were transferred into 
1.5ml tubes. 275µl digestion solution were added to each sample and incubated 
over night (ON) at 55 °C. The next day, 250µl SV lysis buffer was added and vor-
texed. Mixture was transferred to minicolumns and spinned for 3min with 13000g. 
The flow-through was discarded, 650µl  wash solution added to the column and 
centrifuged for 1min with 13000g. Washing was repeated for 3 times followed by 
centrifugation for 2min at 13000g. Then matrix was dried by 2min centrifugation 
with 13000 g. For elution, the columns were placed in new 1.5ml microcentrifuge 
tubes and 250µl nuclease-free water was added on the matrices. After 2min incub-
ation the columns were centrifuged 1min with 13000g. This step was repeated once 
using the eluate from the previous step, to increase DNA concentration.
 2.1.2 Polymerase Chain Reaction (PCR)
In the polymerase chain reaction sequence specific primers bind to DNA and allow 
amplification by Taq polymerase (Promega 5u/µl). The transgene and one house-
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keeping gene were enriched to identify the genotype of each animal. 
Primers:
• Primermix for housekeeping gene
APP-1: 5´- AAG CGG CCA AAG CCT GGA GGG TGG AAC A-3´
APP-2: 5´- GTG GAT AAC CCC TCC CCC AGC CTA GAC CA-3´
• Primermix for APP transgene
APP-2: 5´- GTG GAT AAC CCC TCC CCC AGC CTA GAC CA-3´
APP-4: 5´- TGG ACG ATC TCC AGC CGT GGC ATT C-3´
Reagents used for one PCR reactions were mixed in 200µl thin wall PCR tubes:
Tubes were placed into Biometra T3 Thermocycler and the following PCR program 
was performed:
• 90°C for 2min. (DNA-denaturation step)
• PCR amplification: 35 cycles of:
90°C for 15sec. (denaturation of basepairs)
57°C for 30sec. (annealing of primers)
72°C for 90sec. (elongation of primers)
• Final extension:
72°C 5min.
4°C hold
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 2.1.3 Gel electrophoresis
Gel electrophoresis was used to separate DNA in an agarose gel with respect to 
different size, thus the outcome of the PCR can be visualised. A 1.2% agarose gel 
was poured. Therefore 0.6g agarose (Invitrogen) were dissolved in 1xTAE by heat-
ing it up in the microwave. For detection of the nucleic acid the intercalating reagent 
SYBR safe (Invitrogen) was added to liquid agarose before the gel was casted. 
Samples for gel electrophoresis were mixed with loading buffer and separated by 
10V/cm of the gel. DNA ladder used as standard was FastRuler DNA ladder low 
range (Fermentas). The UVP UV-Transilluminator was used for detection of DNA 
signals. 
 2.2 Histochemical Analysis
For all  experiments Tg2576 respectively wt  129S2 mice were used.  Mice were 
killed by decapitation. Blood was collected, brains were removed immediately and 
tail  tips  were  used  for  genotyping.  The  blood  samples  were  centrifuged  at 
10000rpm for  10min.  The  supernatants  were  stored  at  -20C°  marked  as  sera. 
Brains were prepared for both histochemical and biochemical analysis. For the his-
tochemistry one hemibrain was fixed in 4% paraformaldehyde, for the biochemical 
approach the other hemibrain was snapfrozen in liquid nitrogen and stored at -80°C 
until further use. 
 2.2.1 Brain fixation and dehydration
The hemibrains which have been used for histochemistry, were fixed and dehyd-
rated to be further sectioned with the microtome. After over night (ON) incubation in 
4% PFA (VWR) at 4°C, the following steps were performed:
1- Wash 30min in PBS 
2- Incubate 2h in 30% EtOH (Merck) solution, then 1h in a fresh 30% EtOH solu-
tion
3- Incubate 2x2h in 50% EtOH solution
4- Incubate over the weekend in 70% EtOH solution
5- Incubate 30min in fresh 70% EtOH
6- Incubate 2x1,5h in 90% EtOH solution
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7- Incubate 2x1,5h in absolute EtOH
8-  Incubate 10min in Xylene (Roth) in glass beakers 
9- Incubate ON in liquid Paraplast (Roth)(in open tubes – Xylene can evaporate)
10-  Incubate in fresh liquid paraffin for 4h
11- Embed the hemibrains with the embedding molds and cassettes
 2.2.2 Sectioning
Tissue sections  of  7µm thickness were  made with  microtome (Leitz  1516)  and 
placed on glass slides (ThermoScientific). Slides were dried at RT for at least one 
night before the sections were stained with different agents. 
 2.2.3 Deparaffinisation and Rehydration of Sections
For all staining procedures first the paraffin has to be removed from the sections 
and they have to be rehydrated. For this procedure slides were put into appropriate 
glass jars.
1- Xylene 1: 5min
2- Xylene 2: 5min
3- Ethanol Absolute: 5min
4- Ethanol Absolute: 2min
5- Ethanol 70%: 2min
6- Ethanol 50%: 2min
7- Ethanol 30%: 2min
8- ddH2O 
Steps 1, 2 and 3: under the fume hood!
 2.2.4 Immunohistochemistry (IHC)
Immunohistochemistry benefits of the high affine binding between antibody and an-
tigen. This interaction allows meticulous detection and distinction of different cell 
types or protein accumulations or alterations in certain areas of tissue sections. 
Bound antibodies were visualised through an enzymatic reaction which leads to 
colour development. This signal is amplified through the avidin-biotin complex. 
Primary antibodies: 
Ms monoclonal 3A5 (AFFiRiS AG) 1:1000
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Ms monoclonal anti-NeuN (Millipore) 1:500
Rb polyclonal anti-GFAP (Chemicon, Millipore) 1:500
Secondary antibodies: 
Goat anti-mouse IgG biot. (H+L) (Vector Labs) 1:250
Anti-rabbit IgG biot. (Vector Labs) 1:250 
(All antibodies were diluted in protein concentrate (MOM Kit, Vector) in PBS)
After deparaffinisation and rehydration antigen retrieval (AR) was performed using 
pH9 and pH6, respectively. Therefore slides were put into a plastic jar filled with 
250ml of pre-warmed (RT) AR solution (DAKO) (in case of double staining, the op-
timal  AR for  both  antibodies  has  been ensured).  They were  heated  in  the  mi-
crowave (3min with maximal power, 10min with 360W). After cooling down to RT, 
slides were washed with PBS (all washing steps were repeated twice). Endogen-
ous peroxidase was blocked by 10min incubation at RT in 3% H2O2 (Merck) diluted 
in PBS. After the next washing step slides were blocked for 1h at RT in MOM block-
ing solution (MOM Kit, Vector Labs; 1 drop in 1.25ml of PBS) in a humidified cham-
ber. Next, slides were washed and then incubated with the primary antibody in a 
humidified chamber over night at 4°C (in case of a double staining, both primary 
antibodies - arose in different species - were incubated together). On the following 
day sections were washed followed by incubation with biotinylated anti-primary an-
tibody in a humidified chamber at RT for 30min. The ABC solution (Vector Labs; 1 
drop of reagent A and one drop of reagent B in 2.5ml PBS) is prepared 30min in ad-
vance. It is applied on the slides for 30min at RT in a humidified chamber after two 
inserted washing steps. Then, slides were washed twice with PBS and once with 
ddH2O. DAB solution (Vector Labs) is prepared (1 drop of Buffer Stock Solution, 2 
drops of DAB Stock Solution and 1 drop of Hydrogen Peroxide Solution were well 
mixed in 2,5ml PBS) and applied on slides at RT for about 5min (depending on col-
our development, which was checked under the microscope regularly). Staining re-
action is stopped with  ddH2O and sections were counterstained with hematoxylin 
(Sigma) for about 2min (colour is developed by rinsing slides in tap water). 
(In the case of double staining, the counterstain was omitted. After DAB incubation 
slides were washed with ddH2O and PSB, followed by 30min incubation with the 
other secondary antibody. The ABC step was repeated with the appertaining wash-
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ing steps. As the substrate for this secondary antibody HistoGreen (Linaris) was 
used. Therefore 2 drops of HistoGreen Chromogen and 2 drops of H2O2 were prop-
erly mixed in 1ml HistoGreen buffer.  The solution was supplied for 5min on the 
slides. Reaction was controlled permanently under the microscope and stopped 
with 1xPBST followed by ddH2O. Sections were rapidly dehydrated in three times 
30sec EtOH abs. and two times xylene for 30sec. Permanent embedding as usual)
Subsequently, brain sections were dehydrated:
1- Ethanol 30%: 2min 
2- Ethanol 50%: 2min 
3- Ethanol 70%: 2min 
4- Ethanol abs: 2min (2x)
5- Xylene 2: 2min 
6- Xylene 1: 2min 
Steps 4, 5 and 6: under the fume hood
Slides were coverslipped with Entellan Neu Mounting Medium (Merck) and micro-
scope cover glasses (ThermoScientific) for Mirax scanning (Zeiss).
 2.2.5 Immunoflourescence staining (IF)
The method works in the same way as IHC only the visualisation differs. Flouro-
phore-tagged antibodies were used and detected via illumination with light of a spe-
cific wavelength. The signal reflects the real amount of the molecule of interest. 
Primary antibodies: 
Ms monoclonal 3A5 (AFFiRiS AG) 1:200
Ms monoclonal anti-MAP2 (Millipore) 1:250
Ms monoclonal anti-NeuN (Millipore) 1:400
Rb anti-α-synuclein AB5038 (Chemicon, Millipore) 1:200
Secondary antibodies: 
Fluorescein goat anti-mouse IgG (H+L) (Vector Labs) 1:100
Texas Red goat anti-rabbit IgG (H+L) (Vector Labs) 1:100
Fluorescein goat anti-rabbit IgG (H+L) (Vector Labs) 1:100
(All antibodies were diluted in 4% normal goat serum in 1xPBST)
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The protocol of DAB staining is performed until sections were cooled down to RT 
after AR, beside the fact that for all washing steps 1xPBST was used instead of 1x-
PBS. Then, slides were directly put in blocking solution (4% NGS in 1xPBST) for 1h 
at RT. Incubation with first antibody follows, ON at 4°C (in the case of double stain-
ing, primary antibodies – gained of different species - were incubated together). 
The next day, sections were washed and incubated with the secondary antibody for 
30min at RT (double staining: both primary antibodies were incubated together). 
After two following washing step, slides were washed for 5min in  ddH2O. Finally, 
slides were coverslipped with vectashield mounting medium containing DAPI (Vec-
tor Labs). The next day dried slides were scanned with Mirax Scan (Zeiss). They 
were stored in the dark at 4°C.
 2.2.6 Congo Red (CR) Staining
Staining Solutions
NaCl Stock Solution sat. 
30g NaCl (VWR) and 200ml ddH2O were well mixed, addition 
of 800ml EtOH abs.
NaCl Working Solution 
50ml NaCl Stock Solution, 0.5ml 1% NaOH (Merck)
Congo Red Stock Solution, sat. 
1g Congo Red Powder (Sigma) and 500ml NaCl Stock Solu-
tion were well mixed
Congo Red Working Solution 
50ml Congo Red Stock Solution, 0.5ml 1%NaOH
As this staining method always was used in combination with immunofluorescent stain-
ings, sections were rehydrated as usual. Also the AR and two following washing steps 
with PBST were performed. Then, slides were placed into freshly prepared NaCl Work-
ing  Solution  for  20min  followed by 1h incubation  in  freshly  filtered (whatman filter, 
VWR) Congo Red Working Solution. Slides were washed with PBST twice. Afterwards 
the normal IF protocol was followed (see above).
 2.2.7 Image Analysis using Fiji software (version fiji-win32-20100614)
For image analysis Fiji software program (version fiji-win32-20100614) in combination 
21
with MIRAX viewer has been used. For detailed description of evaluation protocol see 
chapter 3 at the appropriate sections. 
 2.3 Biochemical Analysis
 2.3.1 Extraction of murine brain tissue
Buffers required:
Homogenisation buffer I (HBI) for 20 mL: 1mL 1M HEPES (Sigma) (pH 7.3), 0.2mL 
0.5M EDTA (Sigma), 18.8mL ddH2O and 2 protease inhibitor (PI) cocktail tablets (com-
plete mini)(Roche)
Homogenisation buffer II (HBII) for 20mL: 9.56g of Guanidin-HCl (Roth) were dis-
solved in 13mL ddH2O, addition of 1mL of 1M HEPES (pH 7.3), 0.2mL of 0.5M EDTA 
and 2 PI cocktail tablets (complete mini)
Dilution buffer for 80mL: 2mL of ice-cold 1M HEPES (pH 7.3), 50µL of 0.5M EDTA 
and 8 PI cocktail tablets (complete mini), the volume was filled to 80mL with ddH2O 
1- Each hemibrain and muscle was homogenised in 1mL of ice-cold HBI using 
a douncer. Samples were always kept on ice and foaming of suspension 
was avoided. Homogenates were transferred into an ultracentrifuge-extra-
safe 1.5mL tube and stored at -80°C until further processing. 
2- Then homogenates were ultracentrifuged at 4°C and 40000 rpm for 30min. 
Supernatant was aliquoted and stored at -80°C as soluble fraction.
3- Pellet was resuspended in 1mL of HBII and incubated 3h at 4°C with con-
stant rotation. The resulting suspension was diluted in 4mL of ice-cold dilu-
tion buffer and then centrifuged at 4°C and 13000rpm for 20min. The super-
natant was aliquoted and stored at -80°C as insoluble fraction. The pellet 
was discarded.
 2.3.2 Dialysis of brain insoluble fractions
Dialysis  cassettes  (10000MWCO;  ThermoScientific)  were  washed  for  at  least 
10min in  ddH2O. Insoluble brain samples were carefully transferred into dialysis 
membranes using a syringe and dialysed against 5L of PBS for 1h at RT with slow 
agitation. For ON dialysis samples were transferred in new cold buffer at 4°C. The 
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next day membranes were transferred into fresh PBS (5L) again and dialysed three 
more hours at 4°C. Dialysed homogenates were transferred into a 1,5ml plastic 
tube and stored at -80°C marked as dialysed insoluble fraction.
 2.3.3 Enzyme Linked ImmunoSorbent Assay (ELISA)
6 different ELISA Kits have been used to determine the amount of three different 
neurotransmitters, a neuroprotective factor and one protein in mouse brain homo-
genates:
 2.3.3.1 Serotonin ELISA (IBL international)
The assay follows the principle of a competitive ELISA whereby biotinylated and 
non-biot. antibody compete for the immobilized antibody binding sites. The OD at 
405nm (reference wavelength: 600-650nm) was measured and the serotonin con-
tent (ng/ml) has be calculated via the 4-parameter program (Tecan Sunrise reader). 
Standard provided: 0.0 ng/ml, 0.08 ng/ml, 0.24 ng/ml, 0.73 ng/ml, 2.2 ng/ml, 6.6 
ng/ml, 19.8 ng/ml
Procedure:
Samples and provided controls were acylated before ELISA procedure. Therefore 
20µl of the brain homogenates and controls were mixed with assay buffer and acyl-
ation reagent and incubated (15min, 37°C). For this purpose disposable glass cent-
rifuge tubes (Corning) has been used. Subsequently 2ml assay buffer was added 
and the mixture was centrifuged for 10min at 1500g. 
50ml of the supernatant of acylated samples and controls were pipetted into the ap-
propriate  wells  of  the microtiter  plate.  Serotonin Biotin and serotonin  Antiserum 
were added and covered plate was incubated for 90min at RT on an orbital shaker 
(500rpm). After properly washing the wells with provided washing buffer, enzyme 
conjugate was added, followed by further incubation for 60min (same conditions). 
Next, after another washing step, substrate solution was added; incubation 60min 
(same conditions). The reaction was stopped by the addition of stop solution and 
OD was measured. 
 2.3.3.2 Dopamine ELISA (IBL international)
This assay is based on the principle of a sandwich ELISA. The microtiter plate is 
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precoated with goat anti-rabbit antibodies. The antigen in the samples and controls 
were captured by a liquid antibody, which binds to the coated antibody. Detection 
occurs via an enzyme-coupled second antibody binding sites. The signal produced 
by the substrate is proportional to the Dopamine amount in the sample. The OD is 
measured at 405nm (reference wavelength: 600-650nm) and the dopamine content 
(ng/ml) has be calculated via the 4-parameter, cubic spline and LogitLog program 
(Tecan Sunrise reader). 
Standard provided: 0.0 ng/ml, 60 ng/ml, 180 ng/ml, 585 ng/ml, 2300 ng/ml, 11470 
ng/ml
Procedure:
Samples, supplied controls and standards were extracted before ELISA procedure. 
Therefore 50µl or 100µl of the brain homogenates and 20µl of standards and con-
trols  were  mixed  with  extraction  buffer  and  incubated  (30min,  RT,  800rpm)  in 
provided extraction plates. Subsequently, wells were washed with ddH2O 5min on 
the shaker. Then, extraction buffer and acylation reagent were added and extracted 
20min (RT, 500rpm). After another washing step, incubation with release buffer fol-
lowed (30min, RT 500rpm). The resulting samples were diluted in release buffer 
1:51. 
75ml  of  freshly  prepared COMT Enzyme Solution  were  applied  into  each well. 
100µl of the diluted extracted samples and controls were added as well  as 50µl 
Dopamine Antiserum. The covered plate was incubated for 120min at RT on an or-
bital shaker (500rpm). After properly washing the wells with provided washing buf-
fer, enzyme conjugate was added, followed by further incubation for 60min (same 
conditions). Next, after another washing step, substrate solution was added; incub-
ation 40min (same conditions). The reaction was stopped by the addition of stop 
solution and OD was measured. 
 2.3.3.3 Mouse acetylcholine (ACH) ELISA Kit (Cusabio Biotech co.,  
Ltd)
This kit is based on the principle of a sandwich ELISAs (see above). TMB is used 
as substrate for the horse radish peroxidase and the signal obtained is proportional 
to the quantity of murine ACh in the brain homogenates. 
Standard provided: 0.15 ng/ml, 0.312 ng/ml, 0.625 ng/ml, 1.25 ng/ml, 2.5 ng/ml, 5 
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ng/ml, 10 ng/ml
Procedure:
100µl of diluted (1:5) samples, standards and blanks were pipetted as duplicates 
into precoated wells of the microtiter plate. After incubation for 2 hours at 37°C, 
100µl of the biotin-labelled antibody was added and incubated for one more hour at 
37°C. After washing the wells, HRP-avidin working solution was added; incubation 
for 1h at 37°C. Subsequently, another washing step was performed before TMB 
substrate was applied for 10-30min at 37°C depending on colour development. Re-
action  was  stopped  with  stop  solution  and  the  OD  was  measured  at  450nm 
wavelength with Tecan ELISA reader and the adequate program of Magellan was 
used to obtain a standard curve and the corresponding equation. Thus, concentra-
tions of the protein of interest can be determined in samples. 
 2.3.3.4 Human sAPPα (highly sensitive) Assay Kit (IBL international)
Both sAPPα kits are sandwich ELISAs (see above). TMB is used as Chromogen 
and the obtained signal is proportional to the quantities of human/murine sAPPα in 
the samples. 
Standard provided: 0.78 ng/ml, 1.56 ng/ml, 3.13 ng/ml, 6.25 ng/ml, 12.5 ng/ml, 25 
ng/ml, 50 ng/ml
Procedure:
100µl of diluted (1:100 for both assays) samples, standards and blanks were pipet-
ted as duplicates into precoated wells of the microtiter plate. After incubation over 
night at 4°C, plate was washed. Then the labelled antibody was added and incub-
ated for 30min at 4°C. The plate was washed again and the substrate was added; 
incubation for 30min in the dark at RT. Reaction was stopped with stop solution and 
the OD was measured at 450nm wavelength with Tecan ELISA reader and the ad-
equate program of Magellan was used to obtain a standard curve and the corres-
ponding equation. Thus, concentrations of the protein of interest can be determined 
in samples. 
 2.3.3.5 Mouse/Rat  sAPPα (highly  sensitive)  Assay Kit  (IBL interna-
tional)
Standard provided: 10 pg/ml, 20 pg/ml, 40 pg/ml, 80 pg/ml, 160 pg/ml, 320 pg/ml, 
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640 pg/ml
Same principal and procedure as in 2.3.3.4.
 2.3.3.6 ELISA Kit for Mouse Microtubuli Associated Protein 2 (MAP2)  
(Uscn Life Science Inc. Wuhan)
This assay is based on the principle of a sandwich ELISA. The microtiter plate is 
precoated with a MAP2 specific antibody which captures the antigen in the samples 
and controls. Detection occurs via an enzyme-coupled second antibody. The signal 
produced by the added substrate is proportional to the MAP2 concentration in the 
samples. The OD is measured at 450nm and the MAP2 content (ng/ml) has be cal-
culated via the 4-parameter program (Tecan Sunrise reader). 
Standard provided: 0.15 ng/ml, 0.312 ng/ml, 0.625 ng/ml, 1.25 ng/ml, 2.5 ng/ml, 5 
ng/ml, 10 ng/ml
Procedure:
100µl of diluted (1:20) samples, standards and blanks were pipetted as duplicates 
into precoated wells of the microtiter plate. After incubation for 2 hours at 37°C, 
100µl of detection reagent A working solution was added and incubated for one 
more hour at 37°C. After properly washing the wells, 100µl of detection reagent B 
working solution was added; incubation for 30min at 37°C. Subsequently, another 
washing step  was  performed before  the  substrate  solution  was  applied  for  15-
25min at 37°C. Reaction was stopped with stop solution and the OD was measured 
at 450nm wavelength with Tecan ELISA reader immediately. 
 2.3.4 Western Blotting
Also in the western blot technique the binding between antigen and antibody is util-
ised. Proteins were separated according to their molecular weight in the electro-
phoresis. The protein of interest further can be easily identified by the incubation 
with the specific antibody and the following application of the HRP-labelled second-
ary antibody. The signal can be visualised by luminescence. 
 2.3.4.1 Bradford protein assay
Determination of protein concentration in a homogenate was done by Bradford as-
say. The dye reagent changes from red to blue by cationic and hydrophobic protein 
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binding with an absorbance maximum at 595 nm wavelengths. 
For analysis the dye reagent concentrate (BioRad) was diluted 1:5 with ddH2O and 
filtered (whatman filter, VWR) to remove precipitates. BSA (2mg/ml; Pierce) serial 
dilutions were used as a standard (concentrations see below). Samples were di-
luted 1:8 (insoluble fractions) and 1:40 (soluble fractions) and used in duplicates. 
10µl BSA standard or protein samples were pipetted on micotiterplates (Nunc) and 
200 µl dye reagent was added and mixed. Plates were incubated at RT for 5min 
and then absorbance was measured at 595 nm wavelength with a plate reader 
(Tecan Sunrise). 
Standard  concentrations:  0.50mg/ml,  0.40mg/ml,  0.30mg/ml,  0.20mg/ml, 
0.10mg/ml, 0.05mg/ml (pure ddH2O is measured as blank)
 2.3.4.2 SDS polyacrylamide gelelectrophoresis (SDS PAGE)
For the separation of proteins a polyacrylamide gel containing SDS was used, sep-
arating the molecules according to their molecular size. 
For analysis a 4% acrylamide stacking gel and 10% (for proteins of MW between 
30-120kD) or 12% (for proteins smaller than 30kD) acrylamide running gel were 
poured. For MAP2 Western Blotting 4-12% gradient gels from NuPAGE were used. 
The gradient allows separation of proteins from ~40kD (β-actin) to 250kD (MAP2). 
Homogenized brain samples (soluble and dialysed insoluble fractions; dialysis pro-
tocol see above) were diluted with ddH2O and mixed with sample buffer. Then pro-
teins were denaturated at 90°C for 5min. 20µg total protein (determined by Brad-
ford Assay, see above) were loaded on the SDS gel. 5µl protein ladder (PageRuler 
Plus prestained Protein Ladder, Fermentas) was loaded on each gel to indicate the 
size. Electrophoresis was performed in the gel chamber (Biorad, MGV-202) filled 
with 1x running buffer; 1x MOPS running buffer (NuPAGE) for gradient gels. 15mA 
per gel were applied (Power supply - Biorad, Power Pac). Gel run was stopped 
when front line moved far enough.
 2.3.4.3 Western Blot
Primary antibodies: 
Ms monoclonal anti-PSD95 (abcam) 1:1000
Ms monoclonal anti-Drebrin (abcam) 1:800
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Ms monoclonal anti-MAP2 (Millipore) 1:4000
Rb polyclonal anti-α-synuclein AB5038 (Chemicon, Millipore) 
1:2000
Rb polyclonal anti-ARC/Arg3.1 (Acris) 1:1000
Rb polyclonal anti-β actin (Novus Biologicals) 1:2000
Secondary antibodies: 
Goat anti-mouse HRP IgG+IgM (H+L) (Jackson) 1:20000
Goat anti-rabbit IgG F(ab)2-HRP (Jackson) 1:20000
(All antibodies were diluted in 5% milk powder in PBST)
The samples were separated by SDS gel electrophoresis according to molecular 
size. Then proteins got transferred voltage-dependent on a 0.2µm pore-size nitro-
cellulose transfer  membrane (Sigma)  For the blotting, sponges, whatmanpapers 
and membranes were soaked in 1x transfer buffer. A sandwich, sponge – filter pa-
per – gel – membrane – filter paper – sponge was assembled. Western Blotting 
was performed in transfer buffer for 45min with 100V (keep cool!) or ON at 4°C with 
15V constant. (Blot chamber – Mini Trans-Blot cell, Biorad). 
Thereafter, membrane was stained with Ponceau S which binds to proteins. Thus, 
complete protein transfer to the membrane can be confirmed. The membrane was 
used directly for further experiments or stored at 4°C until further use. 
Membrane was washed in PBST and blocked 1 hour with 5% (w/v) milk in PBST 
(alternatively blocking was done ON at 4°C). Then the membrane was incubated 
with the primary antibody diluted in 5% milk/PBST for 1 hour at RT or ON at 4°C fol-
lowed by 3 times 10min washing with PBST to remove unspecific binding of the an-
tibody. After that, membrane was incubated with the HRP conjugated secondary 
antibody diluted in 5% milk/PBST for 30min at RT and washed two times 10min 
with PBST and once 5min with PBS. ECL+ detection kit (GE Healthcare) was used 
for antibody detection. Signal was evaluated with UVP Bioimaging system. 
After evaluation, the membrane can be stripped and used for another antibody in-
cubation (protocol see below). 
 2.3.4.4 Membrane Stripping
Membrane was incubated for 30min at 50°C with the stripping buffer in a 50mL tube 
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followed by three washing steps with PBST each 10min. Then the standard WB 
protocol can be continued beginning at the blocking step.
 2.3.4.5 Evaluation of WB with fiji-win32 (version fiji-win32-20100614)  
software
One fixed rectangle was laid over each single band on one blot. Next, the program 
measures the intensity of the bands in the chosen rectangles and shows them as 
peaks. Under these peaks manually the background levels have to be drawn for the 
calculation of the peak area. The obtained values for the certain protein band were 
divided by the values measured for the corresponding loading control band (in our 
case  β-actin). Thus, the intensities of the bands are all normalized to the blotted 
amount of protein and can be compared (also blots among each other) in further 
analysis. 
 2.4 Buffers and solutions:
10x PBS (5 litres)
10g KCl (Sigma)
10g KH2PO4 (Merck)
57.5g Na2HPO4 (Sigma)
400g NaCl (VWR)
pH 7.4-7.6
1x PBST (1liter)
100ml 10x PBS
1ml Tween20 (Roth)
900ml ddH2O
Agarose Gel
50 x TAE: (1 litre)
242g TRIS (Roth)
57.1ml Acetic acid (Roth)
100ml 0,5 M EDTA (pH 8,0) (Roth)
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6x Loading Buffer
10mM Tris-HCL (pH 7,6) (Sigma)
0.15% Orange G (Sigma)
0.03% Xylene Cyanol (Sigma)
60% Glycerol (Roth)
60mM EDTA (pH 8,0) (Sigma)
SDS-PAGE and WB
5x Sample Buffer
10%w/v SDS (Fluka)
10mM β-mercaptoethanol (Sigma)
20%v/v Glycerol (Roth)
0.2M Tris-HCl, pH 6.8 (Sigma)
0.05% (w/v) Bromophenolblue (Sigma)
10% Running Gel
ddH2O (Millipore) 12.300 ml
1.5M Tris-HCl, pH 8.8 (Sigma) 7.500 ml
10% (w/v) SDS (Fluka) 0.300 ml
30% Acrylamide (Roth) 9.900 ml
10% (w/v) ammonium persulphate (APS) (Roth) 0.150 ml
TEMED (Roth) 0.020 ml
12% Running Gel
ddH2O 10.200 ml
1.5 M Tris-HCl, pH 8.8 7.500 ml
10% (w/v) SDS 0.300 ml
30% Acrylamide 12.000 ml
10% (w/v) APS  0.150 ml
TEMED 0.020 ml
4% Stacking Gel
ddH2O 3.075 ml
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0.5M Tris-HCl, pH 6.8 1.250 ml
10% (w/v) SDS 0.050 ml
30% Acrylamide  0.670 ml
10% (w/v) APS  0.025 ml
TEMED 0.005 ml
1x Running Buffer (1 litre)
3.03g Tris-HCl (Sigma)
14.4g  Glycine (VWR)
1g SDS (Fluka)
10x Transfer Buffer (1 litre)
30.3g Trizma base (= 0.25 M) (Roth)
144g Glycine (= 1.92 M) (VWR)
1x Transfer Buffer (2 litres)
400ml Methanol (Roth)
200ml 10x transfer buffer
1400ml ddH2O
Stripping Buffer
20mL 10%SDS, 
12.5mL 0,5M Tris HCl pH6,8, 
0.8mL β-mercaptoethanol
67.5mL ddH2O
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 3 Results
The transgenic mouse model Tg2576 for Alzheimer’s disease has been examined 
regarding to alterations in the central nervous system apart from already well stud-
ied neuritic plaques. 
 3.1 Regenotyping
Initial genotyping has already been performed directly after birth of the mice. Re-
genotyping has been done after killing the mice to confirm and to clearly identify the 
transgenic and wildtype animals for further studies. The animals were regenotyped 
by  extraction  of  DNA from  tail  tips.  The  PCR  product  was  loaded  on  a  1,2% 
agarose gel to visualise the outcome (Fig.6). Per animal two different PCRs were 
performed. One with the primer pair specific for the transgene (b), the other with 
primers for a housekeeping gene (a). As controls, DNA samples of animals with 
known genotype were used. A water sample was used to prove the purity of the 
PCR (not shown). 
Figure 6: Exemplary outcome and interpretation of genotyping PCR on a 1.2% agarose gel. a: 
primer mix A for the housekeeping gene; b: primer mix B for the APP transgene; nc: negative control; 
pc: positive control. 
The figure  just  exemplifies  some results.  Of  course,  genotyping has been pro-
ceeded for all animals of all experiments. 
 3.2 Measurement of human and murine sAPPα levels with 
ELISA Kit in two different experiments
Secreted APP fragments, especially sAPPα, are predicted to be neuroprotective as 
it is involved in initial neurogenesis and after injuries. To guarantee the quality of 
the vaccine it is important to show, that the induced antibodies do not crossreact 
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with sAPPα. Especially, it is important that the vaccination has no negative influ-
ence on mouse sAPPα concentrations. On the other hand, it would be an advant-
ageous impact of the vaccine when it leads to a rise of sAPPα in vaccinated anim-
als compared to untreated transgenic animals. 
First we compared tg with wt brain lysates regarding their sAPPα levels. 
Figure  7: Optical density (OD) of murine sAPPalpha measured by ELISA in mice 
brain homogenates. The same samples were analysed applying two different dilutions. 
tg: transgenic; wt: wildtype
We were able to measure human (data not shown) and murine sAPPα levels in the 
brain homogenates (Fig.7). Interestingly, we found more of the neurotrophic APP 
metabolite in tg animals. Since only single samples have been measured, no stat-
istics were done. 
Further analysis of the neuroprotective factor sAPPα comprised two different exper-
iments. Brain homogenates of differently vaccinated tg animals and control animals 
(PBS treated tg animals) involved in crucial preclinical experiments were investig-
ated. The first experiment is a prophylactic vaccination approach in younger anim-
als (first vaccination at the age of 6 months; Aβ accumulation just starts at the be-
ginning of the vaccination). The second one is a therapeutic approach in older an-
imals (first vaccination at the age of 12 months; Aβ deposition is already eminent at 
this time-point). In both groups, animals were vaccinated 6 times in monthly inter-
vals and then sacrificed. Group 1 of both experiment includes control animals that 
were treated with PBS+Alum (aluminium hydroxide). Alum is an adjuvant contribut-
ing to a good Th2 antibody response. KLH (Keyhole limpet hemocyanin) is used as 
carrier, on which every peptide for vaccination usage is coupled. KLH is needed to 
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induce immunogenicity. After coupling to KLH,the peptide is mixed with Alum. Anim-
als  of  group 2 of both experiments were vaccinated with the AFFITOPE AD03-
+Alum and mice of group 5 of MV0408 were treated with the original Aβ1-6 peptide-
+Alum (see table below).
MV0208 MV0408
Age of animals 14 months 18 months
Vaccination approach Prophylactic Therapeutic
Number of groups 2 3
N° of untreated animals 9 9
N° of AFFITOPE/ Aβ1-6 
vaccinated animals
10 7/7
Both the human as well as the murine sAPPα were measured with the appropriate 
ELISA Kits (IBL, Germany). Since the standards provided have different concentra-
tions, the results are demonstrated independently with different scale bars (Fig.8). 
All ELISA results were depicted in ratio to the wet weight (ww) of the hemibrain, de-
termined immediately after brain preparation. In no group of both experiments stat-
istically significant differences were detectable. That applies for both, murine and 
human sAPPα. Thus, we can conclude that at least no worsening in the sAPPα 
treshold  is  caused by  vaccination.  Of  particular  importance  is,  that  the  murine 
sAPPα concentrations in vaccinated animals are not reduced as this could indicate 
a harmful reaction of the induced antibodies versus the host.
For better visualisation of the positive effects of active immunotherapy against Aβ, 
also the Aβ loads of the investigated groups were shown (data taken from Mandler 
et al., manuscript in preparation; MV0408 group 5 has not been examined). This 
results were obtained by doing immunoflourescence staining on brain sections with 
the mouse monoclonal anti-Aβ antibody 3A5 (AFFiRiS AG). Briefly, the staining pro-
cedure was performed as described in chapter 2.2.5 (pH 9 for AR). Slides were 
scanned with Mirax Scan (Zeiss) and calculations of plaque load were done using 
Mirax Viewer and Definiens Software. 
The results of the Aβ load show remarkable decline of the Aβ positive stained area 
in both experiments. In the therapeutic approach total plaque area was shown to be 
36% decreased compared to the transgenic non-treated PBS group; in the prophy-
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lactic approach the Aβ clearing efficacy is even higher (42%). This underlines the 
capability of the AFFITOPE vaccination to remove Aβ peptide from the brain. 
Concluding, no negative effects on sAPPα of active immunization against Aβ can 
be deduced.
Figure 8: Human and murine sAPPα concentrations measured by ELISA in mouse brain 
homogenates. a) experiment MV0408, therapeutic approach; b) experiment MV0208, prophy-
lactic approach. Additional, mean Aβ positive stained areas were shown for both experiments 
(Gr5 of MV0408 has not been examined). Gr 1: PBS+Alum; Gr 2: AD03+Alum; Gr 5:  Aβ1-6 
+Alum; SEM: standard error of the mean
 3.3 Determination of neurotransmitter concentrations in wt 
and tg animals using ELISA
Next, we focused on Neurotransmitters. These endogenous chemicals are involved 
in the signal transmission at chemical synapses. They are stored in synaptic ves-
icles. Neurotransmitters were released into the synaptic gap after the arrival of an 
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action potential. At the postsynapse they bind on their specific receptors and are re-
cycled or inactivated by different mechanisms. In AD patients a reduction of certain 
neurotransmitters is reported [50], [51]. Thus, we compared three different transmit-
ter types in wildtype and transgenic animals by ELISA. 
 3.3.1 Serotonin
In humans, altered serotonin concentrations are associated with pathologic condi-
tions such as schizophrenia, depression, chronic tension headache and hyperten-
sion. In AD patients decreased serotonin amounts were found. This is believed to 
be caused by the death of serotonergic neurons [50]. 
With the provided Kit (IBL, Germany) we were able to detect serotonin in the sol-
uble fraction of mouse brain homogenates. The OD values of the samples were in 
the middle of the standard curve (between 3 and 5 out of 7 standards measured). 
Samples of wt and tg animals of different age were analysed. The mean data are 
shown in the diagram below (Fig.9). 
Figure 9: Serotonin concentrations in mouse brain homogenates. Measure by ELISA. 
wt: wildtype, tg: transgenic, 14: 14 months of age, 18: 18 months of age, SEM: standard er-
ror of the mean, * - significant (p<0,05), ** - highly significant (p<0,005)
Wt and tg  animals  at  the  age  of  14  months  show a  significant  difference  (for 
wt/tg14: t-test, p=0,003, n=5; wt14/18: t-test, p=0,030, n=5).  The older animals do 
not show any difference in the serotonin concentrations. They are quite comparable 
to the value of the younger tg animals. One must note that the number of animals 
measured per group is very small (5) and the standard deviation relatively high. 
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Thus, to prove significance larger groups of animals have to be analysed. Other-
wise the 14 months old wt also can be seen as an outlier as all remaining groups 
show similar serotonin levels. 
In the literature, serotonin is quantified as about 805ng/g of brain wet weight [52]. 
Our results reflect half the amount. The researchers used high performance liquid 
chromatography  with  electrochemical  detection  (HPLC-ECD)  for  their  measure-
ments. Therefore, one can assume that ELISA is not the preferred method to meas-
ure exact concentrations. 
 3.3.2 Acetylcholine
Achetylcholine (Ach) is an important neurotransmitter to investigate as in AD pa-
tients ACh concentrations are strongly decreased. This is the result of the loss of 
cholinergic  neurons.  ACh  plays  an  important  role  in  learning  and  short-term 
memory, i.e. synaptic plasticity. Hence, the cholinergic system is targeted in current 
therapy strategies of AD (see 1.4). We measured ACh with a commercial ELISA Kit 
(Cusabio Biotech Co.,  Ltd.,  China).  The OD  values of the samples were in the 
middle of the standard curve (between 4 and 5  out of 7 standards measured). In 
Figure 10 the mean data from the measurement of differently aged groups, each 
with 3 animals are shown. 
Figure  10: Acetylcholine concentrations in mouse brain homogenates. Measured by 
ELISA.  wt: wildtype, tg: transgenic, 14: 14 months of age, 18: 18 months of age, SEM: 
standard error of the mean, * - significant (p<0,05),
The only significant  difference is  detectable between tg animals of  the different 
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ages (for tg14/18: t-test, p=0,045, n=3). This data must be regarded with suspicion 
as sample number is much too low to suggest a real correlation. To prove that, 
more samples have to be investigated. No vaccinated transgenic animal samples 
were  analysed.  Two  research  groups  published  ACh  concentrations  in  mouse 
brains. They investigated separately different parts of the brain by HPLC-BCD and 
thus obtained values from 16.4 in the cortex to 27.8nmol/g tissue in the forebrain 
(without cortex and hippocampus)  [53] and 21.4 in the frontal cortex up to 81.8n-
mol/g ww in the striatum [54], respectively. After conversion of these values (MW 
ACh: 146.1g/mol), they reach from 2400pg/mg ww to 12000pg/mg ww. Our values 
for the whole hemisphere reflects not even a hundredth of the result.  Thus, we 
must assume that also for this kind of measurement the commercial ELISA kit is not 
suitable.
 3.3.3 Dopamine
Dopamine is a neurotransmitter found in subcortical parts of the brain. AD, gener-
ally, is designated as cortical dementia, whereas other neurodegenerative diseases 
like PD and Huntington's disease with dementia symptoms were defined as subcor-
tical forms of dementia  [55]. Dopamine levels are decreased since dopaminergic 
neurons are dying. In PD this influences the extrapyramidal systems and thereby 
strongly  inhibits  motor  function,  leads  to  depression  and  slowed  cognition 
(bradyphrenia)  [56]. There are reported cases of AD patients with low dopamine 
levels  in  the cerebrospinal  fluid  (CSF) showing the appropriate phenotype  [56]. 
Moreover, dopaminergic neuron loss has been observed in the ventral tegmental 
area (VTA)  [57], a part of the subcortex. Its neurons project into the frontal and 
limbic areas of the cortex. It is assumed that the changes in the dopaminergic sys-
tem are secondary to primary arising neuritic plaques in the cortex. This explains 
why other areas (like the substantia nigra whose neurons project into the basal 
ganglia where no Aβ deposits are found) are unaffected of dopaminergic neuron 
loss [57]. 
We wanted to investigate whether there are any alterations concerning dopamine 
examining serum and brain homogenates from wildtype and transgenic mice. The 
sample concentrations never exceeded the OD shown by the blank (dilution buffer 
provided in the ELISA kit, IBL, Germany)(data not shown). The internal controls al-
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ways were in the given range, thus one can conclude that the procedure was car-
ried out properly.  In the literature, the levels of dopamine in mouse brains have 
been reported to be about 970ng/g ww. This has been determined by HPLC-ECD 
[52]. Our measurements of dopamine levels with the ELISA were not successful 
and not further conducted. 
 3.4 Investigation of synaptic alterations
Synapses present connections between neurons and other neurons or non-neuron-
al cells, respectively. Most neuronal chemical synapses were formed between the 
axon of the information sending neuron and an dendrite of the neuron which is re-
ceiving the information and forwards it to the nucleus. The electrochemical signal 
arriving at the presynapse is transported via neurotransmitters released from pre-
synaptic vesicles into the synaptic gap. At the postsynapse, neurotransmitters bind 
to  their  receptors  and  thereby  transmit  the  signal  to  the  neighbouring  neuron. 
These mechanisms require  intact  conditions  on  both  sites  of  the synaptic  gap. 
Pathologic  alterations of  pre-  and postsynapses (e.g.  by induced destabilization 
and degradation of membrane bound receptors) caused by abnormal protein accu-
mulation, aggregation or decline lead to destruction of the synapse followed by its 
loss.  This in turn is responsible for the eminent decline of memory and cognitive 
function in neurodegenerative diseases.
 3.4.1 Evaluating MAP2 as a dendritic marker via ELISA, Western Blotting 
and Immunofluorescent Tissue Staining
Dendrites are branches of a neuron. Other than the single axon per nerve cell, one 
neuron builds up many dendrites. Their function is to submit the electric signal re-
ceived by another neuron through chemical synapses to the soma of the neuron. 
The dendritic  terminals  and dendritic  spines  (buds along the dendrite)  build  up 
many synapses to neighbouring neurons. Thus, they play a central role in signal 
transmission and in the construction of the neuronal network in the brain. 
Microtubuli associated protein 2 (MAP2) is a commonly used marker for dendrites. 
It stabilizes microtubuli in the dendritic branches, but not in the axon, where this 
function is fulfilled by Tau protein that is also involved in AD pathology. 
The quantification of MAP2 by ELISA (Uscn Life Science Inc., China) was not suc-
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cessful. The OD values obtained by analysing the soluble fractions of brain homo-
genates were never higher than the blank. As blank the dilution buffer provided in 
the kit was used. From that we must assume that the kit is not suitable for our kind 
of investigations. 
As ELISA was not practicable, we went on to Western Blot analysis of brain homo-
genates aiming to compare MAP2 concentrations of wildtype and transgenic anim-
als. MAP2 was mainly found in the soluble fraction of the brain homogenates. They 
were loaded on a gradient gel (NuPAGE) because MAP2 has a very high molecular 
weight (MW) (about 250kD) and β-actin, used as loading control, a low MW (about 
42kD). The 4-12% gradient gel allows separation of all size fractions of interest. 
MAP2 shows a triple band at about 250kD whereof the upper two can be related to 
the two major isoforms of MAP2, MAP2A and -2B (Fig.11). The third one might be 
another  isoform or  even more likely translationally  modified MAP2 through e.g. 
phosphorylation. 
Figure  11: MAP2 Western Blot with soluble fraction of brain homogenates. Protein 
detection by anti-MAP2 antibody and anti-β-actin  as loading control.  14 min exposure 
time. Corresponding graph showing mean MAP2 values of tg and wt animals normalised 
to β-actin. SD: standard deviation
Blots were evaluated using the Fiji software program (see chapter 2.3.4.5). There 
were no differences notable analysing blots on which homogenates of wt and tg 
single  animals  were  loaded (Fig.11).  Nor  by calculating blots  displaying  pooled 
samples (homogenates of 5 tg or wt animals, respectively were pooled and loaded 
onto the SDS-PAGE) differences in the MAP2/actin ratio between tg and wt animals 
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could be detected (data not shown). Therefore we did not go on for further analysis 
with vaccinated animals.
Figure 12: Exemplary chosen amyloid and dendrite double-labelled brain sections, embedded in 
DAPI containing medium (MV0408, group 1). GFP channel: MAP2->dendrites; Texas Red channel: CR 
->amyloid; DAPI channel: DAPI-> cell bodies. a) detail of the parietal cortex; b) detail of cingulate and 
motor cortex; c) detail of hippocampus; d) magnification of dendrites and amyloid plaques from b). Blue 
arrows: amyloid deposits; orange arrows: amyloid deposits in blood vessels (CAA)
Figure 13: Diagram displaying MAP2 intensities in untreated and AFFITOPE vac-
cinated animals. Group 1: PBS+Alum; group 2: AD03+Alum; cgm: cingulate and motor 
cortex, hc: hippocampus, pc: parietal cortex, SD: standard deviation
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Next, immunoflourescence staining was done on brain sections. Samples of the ex-
periment MV0408 were stained. As counterstain, Congo Red was used that stains 
dense cores of congophilic amyloidogenic Aβ aggregates. With the immunohisto-
chemical approach we were aiming to quantify MAP2 positive staining specifically 
in parts of the brain where AD pathology is observed (Fig.12). These mainly implic-
ate the hippocampus and the cerebral cortex. Fiji software program (version fiji-
win32-20100614) was used to measure the intensity of the MAP2 staining in selec-
ted areas. We marked three areas of the brain as described for CAA analysis (see 
chapter 3.4.3.1) (hippocampus, parietal cortex and cingulate and motor cortex) us-
ing mirax viewer software (see Fig.20a for details). Briefly, the chosen tissue areas 
were automatically covered with equally sized, non-overlapping squares by the fiji 
software program. In each of the squares ten smaller squares were randomly gen-
erated by a special makro, so that these squares cover 10% of the selected tissue 
sample. 
In a following step the intensity of the total selected area (e.g. the total marked hip-
pocampus of section one of animal xy) as well as the mean intensity of the small 
squares were evaluated. For both mean values per group and area were calcu-
lated.  As  there  were  only  slight  differences regarding  mean total  area intensity 
versus mean small squares intensity, only the latter one was used for result demon-
stration. The data received are presented in Figure 13. No differences between un-
treated  (group  1)  and  AFFITOPE vaccinated  (group2)  transgenic  animals  were 
measurable using this approach of image analysis.
 3.4.2 Pre- and postsynaptic Markers
For investigation of alterations at the synaptic site, four proteins were chosen. On 
the one hand three postsynaptic proteins were quantitatively compared by Western 
Blot.  PSD95, Drebrin and ARC/Arg3.1 are located in the dendritic  spines where 
postsynapses were formed. On the other hand,  α−synuclein, a small protein loc-
ated at the presynapse has been investigated.
 3.4.2.1 Comparison of  PSD95 concentrations in wt and tg animals 
using Western Blot
Postsynaptic density 95 (PSD95) is a 120 kD protein involved in forming the post-
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synapse. We found it in the insoluble fraction of the brain homogenates. For West-
ern Blot analysis insoluble samples had to be dialysed as they cannot be loaded 
onto gel because of the high detergent concentration (Guanidin-HCl). 
PSD95 shows a double  band at  about  120kD and a light  band at  about  70kD 
(Fig.14). 
Figure  14: PSD95 Western Blot with dialysed insoluble fraction of brain homogenates. 
Protein detection by anti-PSD95 antibody and anti-β-actin as loading control. 60 sec exposure 
time. Corresponding graph showing mean PSD95 values of tg and wt animals normalised to β-
actin. SD: standard deviation
After evaluation of the bands by Fiji program, no difference between wt and tg an-
imals  has been observed (Fig.14).  Also here,  the analysis  of  wt  and tg  pooled 
samples did not show a difference in PSD95/actin amount (data not shown). Im-
munohistochemistry has been performed using this antibody, but only a very weak 
specific staining could be observed in the hippocampus; not allowing quantitative 
analysis.
 3.4.2.2 Comparison of Drebrin concentrations in wt and tg animals 
using Western Blot
Drebrin is an actin binding, postsynaptic protein with highest localisation in dendritic 
spines. Drebrin is best detectable in the insoluble fraction of brain homogenates; 
i.e. samples had to be dialysed before loading onto gel. 
Drebrin migrates at 120kD on the SDS-PAGE (Fig.15). Analysing blots on which 
single animal samples were loaded, no consistent differences could be detected. 
Next, pooled wt and tg samples were blotted and analysed, but this again did not 
show any difference between wt and tg (data not shown). Hence, analysis has not 
been continued with experiments in vaccinated animals. 
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Figure 15: Drebrin Western Blot with dialysed insoluble fraction of mouse brain homo-
genates. Detection with anti-Drebrin antibody and anti-β-actin antibody. 60sec exposure time. 
Corresponding graph showing mean Drebrin values of tg and wt animals normalised to β-actin. 
SD: standard deviation
In addition, immunohistochemical staining with this antibody has been performed. 
Specificity of the staining was reached using DAB staining, but as there was no 
possibility for sensible evaluations, no further experiments were carried out. 
 3.4.2.3 Comparison of ARC/Arg3.1 concentrations in wt and tg anim-
als using Western Blot
ARC/Arg3.1 is also present in dendritic spines.  It is an immediate-early gene for 
memory function and learning processes. The protein is transported to dendritic 
spines where it is involved in synaptic plasticity. ARC/Arg3.1 is present in the sol-
uble fraction of brain homogenates.
Figure 16: ARC/Arg3.1 Western Blot with soluble fraction of brain homogenates. Protein detec-
tion by anti-ARC/Arg3.1 antibody and anti-β-actin as loading control. 5 min exposure time. Corres-
ponding graph showing mean ARC/Arg3.1 values of tg and wt animals normalised to  β-actin. SD: 
standard deviation
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ARC/Arg3.1 is reported to migrate between 45 and 55kD on Western Blot (Fig.16) 
[58], [59]. The upper band might show dimers of the protein even though reducing 
conditions were chosen for the samples and for the gel. Otherwise it can visualise 
unspecific binding of the antibody. No changes between wt and tg could be noted 
(Fig.16), thus the marker was not used for further investigations. This antibody did 
not give any detectable specific signal in IHC/IF. It is important to keep in mind, that 
ARC is induced immediately after stimulation with learning events. Therefore, our 
samples might not be suitable to investigate this protein since the animals were not 
trained within the last 24h before their death. 
 3.4.2.4 The  presynaptic  protein  α-synuclein  analysed  by  Western 
Blotting and Immunoflourescent Staining
α−synuclein is located at the presynapse and therefore can be used as another in-
dicator for the integrity of the synapses. It is found in the soluble fractions in the 
brain homogenates. First, comparison via Western Blotting was performed. 
Figure 17: α-synuclein Western Blot with soluble fraction of brain homogenates. Protein de-
tection by anti-α-synuclein antibody and anti-β-actin as loading control. 8 min exposure time. Cor-
responding graph showing mean α-synuclein values of tg and wt animals normalised to β-actin. SD: 
standard deviation
By WB no different α-synuclein concentrations could be detected between wt and 
tg brain homogenates normalised to  β-actin (Fig.17). No further comparisons re-
garding vaccinated animals were carried out.
Next, to investigate single brain areas IF with the same antibody has been per-
formed. Like for MAP2 analysis, brain sections of animals from group 1 and 2 of the 
MV0408 experiment were stained. 
We found specific punctuate staining around amyloid plaques which are mainly loc-
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ated in the cerebral cortex and the hippocampus (Fig.18a, b). 
Figure 18: Immunohistochemical staining of α-synuclein on brain sections of Tg2576 mice. GFP 
channel: α-synuclein; Texas Red channel: CR->amyloid; DAPI channel: DAPI-> cell bodies (gated out). 
a) amyloidogenic plaque in the cortex surrounded by α-synuclein positive staining (marked with the white 
circle) made of characteristic α-synuclein occlusions (yellow arrows); example for a CR positive plaque 
surrounding α-synuclein spot); b) α-synuclein around same plaque-caused lesion in the cortex as in a); 
the red circle indicates an α-synuclein positive spot without congophilic centre (Texas Red channel gated 
out); c) example for the selected analysis area in the cortex. α-synuclein positive spots (with and without 
CR) were marked. d) example for selected analysis area in the hippocampus. α-synuclein positive spots 
were marked (with and without CR).
This  staining  is  indicating  neuritic  changes  such  as  degenerative  and  breaking 
neurites in the neighbourhood of amyloidogenic plaques. Congo Red staining was 
performed to counterstain for presence of plaques. This also facilitates the analysis. 
Additionally, there is also specific α-synuclein staining detectable in the absence of 
visible or  congophilic  plaques (some marked spots in Fig.18b,c).  These stained 
areas (“spots”) are characterised by green punctuate abnormalities in areas with 
high plaque load that mark neuritic alterations. For evaluation, certain areas in the 
cerebral cortex (parietal cortex) and the hippocampus (exactly the lateral blade of 
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the molecular layer of the dentate gyrus) were defined. In these two parts of the 
brain, all α-synuclein-positive spots, with and without CR-positive cores, were coun-
ted (Fig.18c, d). 
For the demonstration of the data,  α-synuclein positive spots surrounding Congo 
Red stained plaques and only α-synuclein positive stainings are separately shown. 
The counted number of  α-synuclein positive spots were compared between the 
vaccinated and the non-vaccinated animals in both selected brain areas. The res-
ults are depicted in the following diagrams (Fig.19). 
Figure  19: Diagram demonstrating  α-synuclein positive spots counted 
in different areas of the brain. Gr 1: PBS+Alum; Gr 2: AD03+Alum; HC: 
hippocampus;  CTX:  cortex;  CR:  Congo Red;  SEM:  standard  error  of  the 
mean, * - significant (p<0,05), 
No statistically significant differences between the two groups could be noted in 
total.  A slight  decrease  in  overall  α-synuclein  positive  spots  can  be  assumed 
(Fig.19a). By examining the spots surrounging congophilic plaques versus α-synuc-
lein staining without visible Aβ deposition, we found statistically significant decrease 
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of α-synuclein positive spots without CR in the vaccinated animals (Fig.19b; for un-
treated/vaccinated animals in CTX without CR: t-test, p=0,01, n=14/16). However, 
no changes were detectable in the amount of α-synuclein spots with CR. The num-
ber of counted α-synuclein positive spots in the hc is lower than in the cortex which 
can be explained by the much smaller size of the investigated hippocampal brain 
area. In the hippocampus the number of counted spots are very low (from 0 to 4) 
thus statistical analysis did not make sense. Generally, we can assume the results 
to indicate a statistically significant (Fig.19b) amelioration of  α-synuclein positive 
neuritic alterations upon amyloid removal. 
 3.4.3 Alterations coupled to amyloid deposition 
Some general pathologic changes that occur in brains of AD patient are cerebral 
amyloid angiopathy and astrogliosis. The first describes Aβ deposits in blood ves-
sels. The latter is regarding the immune response toward senile plaques. 
 3.4.3.1 Cerebral Amyloid Angiopathy 
Cerebral amyloid angiopathy (CAA) is manifested in vascular deposition of Aβ. 
These deposits are congophilic.  Hence, the beneficial  goal of active vaccination 
against Aβ would also include an amelioration of CAA in treated animals. An in-
crease of CAA levels could be indication of detrimental alterations in Aβ clearance 
and could mark a higher risk for damage of brain and brain vasculature following 
immunotherapy. This analysis in CAA levels is an important confounder of efficacy 
of active vaccination against Aβ as cerebral amyloid angiopathy can lead to closure 
of affected blood vessels and be the cause of apoplexia. This could even mark a 
higher risk for damage in the brain than Aβ plaques do. 
We used the Congo Red stained brain sections of MV0408 (CR costaining was 
done  for  MAP2  and  α-synuclein  staining)  for  CAA analysis  (see  chapter  3.2). 
Hence, two consecutive slides of one animal were evaluated to enlarge the number 
of samples. In three well defined areas of the brain sections (CGM=cingulate and 
motor cortex, HC=hippocampus and PC=parietal cortex) (Fig.20a) 
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Figure  20:  Congo Red staining of amyloid depositions in blood vessels. Texas Red 
channel: Congo Red; GFP channel: α-synuclein. a) areas of the brain chosen for CAA ana-
lysis. b) CAA in the cingulate and motor cortex. c) CAA in the hippocampus. Yellow arrows: 
CAA. Purple arrows: blood vessels without CAA. Blue arrows: congophilic amyloid plaques.
Figure 21: Number of CAA referred to area counted in three parts of the brain. 
Group 1: PBS+Alum; group 2: AD03+Alum; cgm: cingulate and motor cortex; hc: hip-
pocampus; pc: parietal cortex
Congo Red  stained blood vessels were counted. The statistically evaluated data 
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are shown in the diagram below (Fig.21).  We could not find a difference between 
vaccinated and non-vaccinated transgenic animals. This matches quite well  with 
experiences from other experiments performed in our laboratory. It indicates that 
CAA pathology is not worsening in immunised mice and demonstrates that active 
immunization does not exert negative effects on brain functions and the cerebral 
vasculature. 
 3.4.3.2 Astrogliosis
To demonstrate the altered immune activity in AD brains, astrocytes were stained 
on wt, tg and on vaccinated tg mouse brain sections. As expected we could visual-
ise that astrocytes associate with the Aβ deposits in affected brain areas and form 
so called astrocytic foci. 
In Figure 22, parts of the hippocampus and the cortex of wt and differently treated 
tg animals were shown. Glial fibrillary acidic protein (GFAP) is immunostained and 
visualised by using Histogreen as substrate (blue-green colour). Neuronal nuclei 
(NeuN) were visualised by using DAB as substrate (brown colour). Staining reac-
tion of Figures 22c)-d) were stopped earlier than in a) and b), therefore colours are 
lighter. Additionally, Figures 22c)-d) were counterstained with Congo Red to uncov-
er congophilic amyloid deposits. 
It is obvious, that astrocytes aggregate at sites of altered protein accumulation. A 
tenfold increase of GFAP concentrations has been measured in plaque-containing 
areas [11]. There, astrocytes are involved in clearance of the neuritic plaques and 
can be stained by anti-Aβ antibodies. In normal brains they mainly stay in the cor-
pus callosum and are well distributed also in the hc, but never show such clusters 
as they can be observed in AD brains. No quantitative and statistical evaluation re-
garding GFAP and NeuN as marker for astrogliosis and neuronal loss, respectively 
were performed in this analysis. 
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Figure  22:  Immunohistochemical staining of neurons and astrocytes (NeuN antibody: brown dye; 
GFAP antibody: blue-green dye). a) brain section of a <24month old Tg2576 mouse. Astrocytes at the 
sites of amyloid plaque deposits. b) wt brain sample with equally spreading of astrocytes. c) 18 months 
old non-vaccinated Tg2576 brain section with characteristic amyloid depositions. d) 18 months old vac-
cinated tg brain sample. e) cortical area of an untreated animal. d) magnification of cortical astrogliosis. 
hc: hippocampus; black arrows: not/CR-stained amyloid deposits; red arrow: CR-stained blood vessel
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 4 Discussion
The aim of the diploma thesis was to investigate whether Tg2576 mice show neuro-
pathologic alterations as observed in AD patients. Moreover, the influence of active 
immunotherapy  against  Aβ on  these  neuropathologic  hallmarks  should  be  ex-
amined. 
Among the investigated factors was the neurotrophic APP metabolite sAPPα. With 
the commercial ELISA kit we did not measure any significant changes in the con-
centrations of human and murine sAPPα in the soluble fraction of brain homogen-
ates of differently vaccinated and untreated animals. It has been shown that sAPPα 
has a slower turnover in Tg2576 animals than in wildtype mice [60]. Indeed it has 
been demonstrated that an amyloid plaques containing brain needs more neuro-
trophic  support  [61]. That  means that  even higher levels  of  sAPPα were to  be 
measured in transgenic mice than in wildtype mice. These findings are in line with 
the results we obtained by measuring wt and tg animals (see Fig.7).  Tapia-Arani-
cibia et al. assume that sAPPα counteracts the neurotoxic influence of Aβ plaques 
in AD brains. In APP transgenic mouse model, undoubtedly human sAPPα as well 
as human Aβ are produced both in high quantities as the APP gene possesses a 
strong promoter (see chapter 1.5) and the mutation enhances γ−secretase activity 
[62]. 
Finally we can conclude that sAPPα levels are not negatively affected by the vac-
cination. Above all this is of interest for the murine sAPPα levels. It would be dev-
astating when induced antibodies would crossreact  with the neurotrophic factor. 
This could even worsen memory and cognitive functions instead of ameliorating 
them as protection and rescue mechanisms implying sAPPα get lost.
Next,  our  investigations  focused on  different  neurotransmitters.  Again,  we  used 
commercial ELISA kits. We did not obtain any differences between soluble fractions 
of  brain  homogenates  of  wt  and tg  animals  concerning neurotransmitter  levels. 
There  are  several  explanations  for  that.  On  the  one  hand  we  analysed  whole 
hemibrains. This kind of approach does not allow the measurement of little changes 
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in small areas of the brain. As the cholinergic system mainly influences the hippo-
campus and cerebral cortex, it might be possible to measure different amounts of 
ACh in tg and wt animals observing only these regions. Likewise, serotonin is used 
by only 0.1-1% of all synapses. It is produced in the Raphe nucleus located in the 
brain stem and is active in the cortex and cerebellum. By separately analysing 
these parts of the brain, chances of detecting differences could be augmented. The 
same is true for dopamine which is used by about 15% of all nerve cells in the stri-
atum and is very rare in the rest of the brain. On the other hand one might have to 
use another method unlike ELISA. As mentioned in chapter 3.3, researchers were 
able to measure neurotransmitter levels in different brain areas by using HPLC-ED 
in separated areas of mouse brains [52-54]. 
The next step in the project was the investigation of pre- and postsynaptic altera-
tions in APP transgenic animals. Therefore, we did Western Blot analysis of brain 
lysates of wt and tg animals using antibodies specific for different pre- and postsyn-
aptic markers as well as one dendritic marker. 
ARC/Arg3.1 (activity-regulated cytoskeleton-associated protein)  is  an immediate-
early gene.  Its  mRNA is  induced following stimulation of  long term potentiation 
(LTP) and transported to dendrites, where it is meant to be translated [63]. ARC/Ar-
g3.1 plays a essential role in the process of learning and memory as well as in syn-
apse plasticity. Complete KO mice (ARC/Arg3.1-/-) showed a much lower perform-
ance in long-term memory tests (MWM, context dependent fear conditioning, taste 
aversion  memory)  than  wildtype  animals  did  indicating  an  impaired  function  in 
memory and learning. Synapse plasticity is the ability of a synapse between two 
neurons to change its strength. It is build up via LTP and LTD (long term depres-
sion).  ARC/Arg3.1 loss of function mutants show an increase in LTP and a de-
crease in LTD. The discoverers assume that this fact is linked to the decreased en-
docytosis of the AMPA receptor (a glutamate receptor) that is ARC/Arg3.1 mediated 
[64].  Thirty minutes after memory training,  ARC/Arg3.1 is upregulated  [65],  [66]. 
This very fast response might be an explanation why we could not detect any differ-
ence between tg and wt animals. The animals were not trained before they were 
sacrificed. In AD patients, initial increase followed by a decrease of ARC/Arg3.1 has 
been observed. Short exposure to Aβ oligomers enhance ARC/Arg3.1 expression; 
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in contrast long exposure reduce ARC/Arg3.1 basal levels as well as its induction in 
learning situations [67]. 
Drebrin (developmentally regulated brain protein) is an actin binding protein [68]. Its 
molecular weight is about 70kD, but in electrophoresis it also shows a particular 
120kD band  [69]. The isoform Drebrin A is neuron-specific and mainly located in 
dendrites, particularly in dendritic spines  [70], whose biochemical properties, size 
and  form  are  crucial  for  synaptic  transmission.  Moreover  it  is  involved  in  the 
morphogenesis  of  dendritic  spines.  Drebrin  A is  required  for  the  clustering  of 
PSD95 as well as for synapse plasticity [71]. Low concentrations of Drebrin A have 
been associated with trisomy 21 and AD [72]. A decline of Drebrin has been shown 
in Tg2576 [73], [74] as well but could not be reproduced by our analysis. 
PSD95  (post  synaptic  density  95)  is  a  member  of  the  membrane-associated 
guanylate kinase (MAGUK) family. It contains a PDZ domain, which consists of 80-
90 aa allowing to bind a peptide sequence at the C-Terminus of other specific pro-
teins. PSD95 is involved in anchoring synaptic proteins as well as clustering and or-
ganisation of receptors such as NMDARs at the synapses  [75], [76]. Moreover, it 
can drive synaptic maturation at post- but also at presynaptic terminals. Its overex-
pression showed an increase of the number and the size of dendritic spines [77]. 
The presynaptic protein α-synuclein is best known from PD where it forms aggreg-
ates, so called Lewy bodies, the main pathologic hallmark of this disease. It is also 
found in DLB, a form of dementia with Lewy bodies (intraneural aggregation of α-
synuclein near the nucleus). There, it has been shown that dendritic spine retrac-
tion occur rather than complete synapse loss. This is particularly true if there are α-
synuclein aggregates at the presynaptic sites. The researchers found reduction of 
the pre- and postsynaptic  markers (synaptophysin and PSD95) in DLB patients 
compared to non-demented persons and complete loss of Drebrin [78]. The same 
phenomenon could be noted in neostriatal medium spiny neurons in PD [79]. Con-
cluding, it is important to underline the fact that size and number of dendritic spines 
are associated with memory. Inducing LTP leads to the formations of new dendritic 
spines [80]. 
We did not detect any differences between tg and wt animals concerning these 
factors. As mentioned above in the discussion of the ELISA results, the same is 
true for the WB results. When there are small alterations in tg animals compared to 
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wt animals in dedicated areas of the brain, analysis of the full hemibrain might pre-
clude to detect these subtle differences. Also here it applies that only the regions of 
interest should be analysed. In all cases this would implicate the hippocampus and 
the cerebral cortex because there both, the amyloid plaque load and neuron dens-
ity is the highest. This can be done by either preparation of the single brain areas 
followed by biochemical analysis or by region specific immunohistochemical stain-
ings on brain sections. 
The latter has been performed in the case of α-synuclein and MAP2 antibodies. 
Immunohistochemistry of MAP2 gave good insight to the structure and arrange-
ment of dendrites in different brain layers. Even by eye alterations near neuritic 
plaques were easily detectable. Nevertheless, measurements of MAP2 intensities 
in different brain areas did not show amelioration in vaccinated versus untreated 
transgenic animals. We suppose the magnification and resolution of the microscope 
as well as the thickness of the tissue samples (7µm) to be the most problematic 
factors in the type of analysis we performed. There are published data about dend-
ritic spine loss in the mouse model we were using. Lanz et al. found dendritic spine 
loss in CA1 hippocampal neurons and referred that on ageing and APP overexpres-
sion [81]. Besides, Spires-Jones et al. established the theory stating plaques to be 
space-occupying lesions in whose immediate neighbourhood loss of dendrites oc-
curs. However,  amyloid plaques are thought to spread even farer  [82].  In these 
farther areas, soluble Aβ is predicted to be responsible for PSD95 reduction at the 
site of dendritic spines and following AMPAR internalisation [83]. This leads to the 
breakdown of spines  [84]. Dystrophic neurites have been observed in the direct 
neighbourhood of plaques. They only arise at the second day of plaque formation 
or even later indicating that the damage caused to the neurons are caused by Aβ 
plaques [85]. Concluding we can suggest that either the methods we used and the 
approach of analysis that has been chosen are not the best suitable for such kind 
of investigations. 
The immunoflourescence staining of  α-synuclein was successful as well and we 
were able to count the positive stained spots around congophilic amyloidogenic de-
posits and smaller spots without visible plaque associated. As the amyloid plaque 
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load in the therapeutic experiment is 36% decreased in the vaccinated group in 
comparison to the PBS control group (see chapter 3.2, Fig.8a) we would also ex-
pect less neuritic alterations in these animals. In total, we found an insignificant de-
cline in total α-synuclein-positive stainings. Statistically significant results were ob-
tained in the cortex when counting α-synuclein positive spots devoid of visible con-
gophilic deposits. This leads to the conclusion that active immunization against Aβ 
in mice leads to clearance of soluble Aβ and to the removal of dense core congo-
philic Aβ plaques. By the elimination of these small rather soluble Aβ depositions 
also neuritic alterations indicated by  α-synuclein positive punctuate abnormalities 
seem to be diminished.
A certain part of α-synuclein is reported to take part in amyloid plaques as the so 
called non amyloid component (NAC) [86-88]. This is the domain in the α-synuclein 
protein which is responsible for its high prevalence to aggregate and is involved in 
Lewy body formation in PD. One must notice that the α-synuclein staining as we 
found it,  is  not  identical  with  NAC because other  than NAC we  found staining 
around but not in the plaques. Yang et al. also observed the punctuate accumula-
tion of α-synuclein along the perimeter of the plaques in Tg2576 animals [88]. They 
suggest a defect in the proteasome system might be the cause of α-synuclein ac-
cumulation that is also reported to be linked to PD. α-synuclein usually is degraded 
via ubiquitination and following proteasomal degradation. Similar observations to 
ours were made with synaptophysin [89] which is also a presynaptic protein. Dong 
et al. neither found changes in tg and wt animal in overall synaptophysin-positive 
bouton (presynaptic bud) density using quantitative light microscopy. However, with 
electron microscopy they were able to reveal a significant overall decline in syn-
aptic density in tg animals compared to non-transgenic littermates. The analysed 
parts of the brain comprise the outer molecular layer of the dentate gyrus and the 
entorhinal cortex (comparable to the areas we investigated). Additionally, they state 
a correlation between the proximity to amyloid plaques and decrease of synaptic 
density.  Finally  they  assume  that  the  stained  presynaptic  spots  arise  after  re-
arrangement  of  presynaptic  proteins  provoked  by  the  degeneration  of  postsyn-
apses that are depicted in other studies [90]. 
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 5 Conclusion
In our research of Tg2576 we found slight impairments on the synaptic networks 
compared to a wildtype laboratory mouse strain. These changes were visualised on 
the one hand by MAP2 staining in the immediate neighbourhood of amyloid depos-
its. MAP2 reflects the amount of dendrites and their branches, which are highly in-
volved in synapse formation. In transgenic animals the networks of dendrites are 
impaired in certain regions of the brain such as the cortex and the hippocampus. 
This results from amyloid deposits spread in these areas. On the other hand accu-
mulation of  α-synuclein around neuritic plaques allows assumption of worse syn-
aptic function. Soluble α-synuclein usually is present in nearly all areas of the brain 
and is involved in synapse rearrangement at presynaptic sites. Statistically signific-
ant  differences  between  vaccinated  and  non-vaccinated  animals  could  not  be 
shown with the methods we used. Hence, for more insight in whether in our mouse 
model, synapse density and plasticity is improved after vaccination, methods with 
higher resolution have to be used, like confocal microscopy. 
The investigated postsynaptic proteins PSD95, Drebrin and ARC/Arg3.1 were not 
further analysed as no different concentrations in wildtype and transgenic animals 
were  detectable  by  Western  Blotting.  Again,  one  possibility  to  detect  marginal 
changes in  some areas of  the brain more  sensitive  methods have to  be used. 
These would include biochemical analysis of only distinct parts of the brain instead 
of whole hemibrains. Otherwise immunohistochemical protocols can be established 
that allow quantitative analysis. 
This also holds true for the investigation of neurotransmitters. Every transmitter is 
responsible for special neuronal cell types. These are not regularly spread in the 
whole brain,  but with high accumulation in certain areas. Thus, an effect of  the 
transgene might be detectable by analysing single brain areas separately. By ana-
lysing hemibrains we were not able to show any differences. Another explanation 
for that would be that neuronal loss, observed in AD patients  [91-93], has not be 
noted in Tg2576 animals  [11].  Death of  e.g.  cholinergic  neurons leads to a de-
crease of acetylcholine in the affected brain area. Another reason for the unsatisfy-
ing results could be the insufficiency of the commercial kits used for the analysis. 
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Hence, one can say, that for further studying positive impacts of active immuniza-
tion against Aβ apart from plaque clearance and improvement of cognitive functions 
(Mandler et al., manuscript in preparation), one possibility would be to use a differ-
ent animal model,  which shows a stronger phenotype regarding pathologic hall-
marks of AD such as neuronal loss. There are more aggressive mouse models 
available and showing impaired neurotransmission such as the APP23 mouse [94]. 
Mouse models known to show neuronal loss and synaptic dysfunction mostly have 
different mutations in the human APP transgene that is under the control of a neur-
on specific  promoter  and leads to  overexpression.  In  addition,  they carry  other 
transgenes with mutations in the PS1 gene, a crucial part of the γ−secretase protein 
complex responsible for Aβ production [95].
Another possibility to get insight into neuropathologic alterations would be to look 
carefully on the patients participating in the clinical trials. Studying their brains post 
mortem with regard to their symptomatic amelioration in context with synapse and 
neuron loss could be most illuminative. 
In conclusion, we can assume amelioration in vaccinated mice regarding all mark-
ers which are in the immediate neighbourhood of neuritic plaques,  such as astro-
cytosis (Mandler et al., manuscript in preparation), density of dendrites, neuritic and 
presynaptic alterations as well as cognitive function. This gives hope for beneficial 
properties of the vaccine on AD associated alterations also in humans. 
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